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 Abstract 
Of the 3.5 million persons infected with chronic HCV in the United States, the African 
American population is the largest racial group with chronic HCV.  Disparities in access 
to care and treatment involve a complex set of individual, interpersonal, socioeconomic, 
and environmental factors that influence the course of HCV infection in the African 
American population, resulting in poorer outcomes and survival.  Drawing upon both the 
theory of reasoned action and the theory of planned behavior, this study was conducted to 
determine whether the seeking of health care by HCV-positive African Americans and 
the responses of health care providers to HCV-positive African Americans had improved 
since 2008 following the introduction of new treatment options, as compared to other 
HCV-positive racial/ethnic groups, using secondary data analyses with survey datasets 
from the National Health and Nutrition Examination Survey, 2005-2012.  Using chi-
square test of difference and logistic regression analyses, the study did not identify a 
statistically significant relationship between health care seeking behavior and responses 
from health care providers for HCV-positive African Americans before (2005-2008) and 
after (2009-2012) the introduction of new treatment options as compared to other HCV-
positive racial/ethnic groups.  Given the ongoing development of new and improved 
drugs to treat HCV infection, further research might focus on the HCV-infected 
population as a whole to ascertain whether differences exist as compared to earlier 
therapies before 2013.  This study may drive social change within the health care 
community by raising awareness of the risks of HCV infection resulting in less provider 
bias and the introduction of resources into the African American and underserved 
communities that will improve outcomes and reduce barriers to care. 
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Chapter 1: Introduction to the Study 
Introduction 
There are approximately 3.5 million people with chronic hepatitis C virus (HCV) 
infection in the United States (Centers for Disease Control and Prevention, 2012a).  
African Americans have a two-fold higher prevalence (3.0%) compared to Caucasians 
(1.3%) and Hispanics (1.5%; Kemmer & Neff, 2010).  In addition, HCV-infected African 
Americans are disproportionately affected when it comes to HCV-related morbidity, 
mortality, access to care, quality of care, and treatment response.  African Americans 
have poorer health outcomes, including a two-fold higher rate of liver cancer, a 2- to 3-
times higher rate of liver cancer-related mortality, and lower rates of survival from liver 
transplantation (Layden et al., 2012; Pearlman, 2006).  Since 2008, newer treatment 
options have been available for HCV infection; prior to 2008, the treatment for HCV 
infection had remained the same for 13 years.  Although previous researchers have 
examined health disparities in HCV-infected African Americans, very little research has 
been published concerning this cohort since newer treatment options were made available.  
Understanding the association between health disparities in HCV-infected African 
Americans since the introduction of newer treatment options could help public health 
professionals and healthcare providers develop strategies for eliminating health 
disparities affecting HCV-infected African Americans, including earlier prevention 
measures employing community-based clinics, providers, and resources for low 
socioeconomic communities to promote antistigmatization and better access and 
treatment.  The most recent data on HCV infection in the U.S. population were collected 
by the 2011-2012 National Health and Nutrition Examination Survey (NHANES).  The 
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research used the NHANES datasets for an 8-year period (2005-2012) to examine the 
health care seeking behavior and provider responses of HCV-positive African Americans. 
In this chapter, I discuss the current status of HCV infection in the United States 
and provide a brief summary of the relation between HCV infection and African 
Americans.  I also describe the specific goals of the research, the hypotheses tested, and 
operational definitions.  In addition, I discuss the scope, assumptions, delimitations, and 
limitations of the study.  Finally, I provide a brief summary of the expected significance 
of the results as they relate to advancing knowledge, practice, and social change. 
Background 
In the United States, HCV is a major cause of chronic liver disease, end-stage 
liver disease, and liver cancer (Centers for Disease Control and Prevention, 2012a).  
Among persons who acquire HCV, 20% to 25% will naturally clear the virus; the 
remaining will not clear the virus and will become chronically infected with HCV 
(Centers for Disease Control and Prevention, 2012a).  Over the period of the first 20 
years, 20% of persons with chronic HCV will develop cirrhosis (permanent scarring of 
the liver); one to seven persons with chronic HCV will develop liver cancer yearly 
(Centers for Disease Control and Prevention, 2012a; Kanda, Yokosuka, & Omata, 2013). 
Major causes of death in the HCV-infected population are end-stage liver disease and 
liver cancer; the only therapeutic option is a liver transplant (Layden et al., 2012).  Most 
persons infected with HCV do not experience symptoms and will only seek medical 
attention in the late stages of liver disease when symptoms finally appear. 
HCV infection is more prevalent in the African American population than in any 
other racial group.  Although African Americans represent only 13% of the U.S. 
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population, they make up almost one quarter (22%) of all HCV cases (Centers for 
Disease Control and Prevention, 2012a).  End-stage liver disease from HCV is one of the 
leading causes of death for African Americans between the ages of 45 and 64 (Pearlman, 
2006).  Overall, there is a two-fold higher incidence of HCV-related mortality for African 
Americans as compared to non-Hispanic Whites (Saab, Jackson, Nieto, & Francois, 
2014).  African Americans infected with HCV have poorer health outcomes and lower 
rates of survival from liver transplantation (Layden et al., 2012; Pearlman, 2006).  When 
African Americans infected with HCV are given the current treatment, their rates of 
sustained viral response (SVR) and viral clearance are lower compared to Caucasians 
(Burton, Passarella, & McGuire, 2012).   
The major risk factor for HCV infection is injection drug use.  The overall rate of 
HCV infection is estimated at between 60% and 90% among injection drug users (IDUs); 
in addition, 60% of new HCV cases occur in this cohort (Nelson et al., 2011).  African 
Americans have a higher prevalence of injection drug use, which contributes to their 
higher rate of HCV infection (Amon et al., 2008).  Results from the 2011 National 
Survey on Drug Use and Health found that reported illicit drug use within the past month 
was highest for the following groups: (a) African Americans (10%), (b) males (9%), (c) 
ages 18-25 (23.8%), (d) those who did not graduate from high school (11.1%), and (e) 
unemployed (17.2%; U.S. Department of Health and Human Services, 2012).  Studies 
have found that African American injection drug users have a greater burden of injection-
related health issues, including higher HCV rates, as compared to non-Hispanic White 
injection drug users (Jordan et al., 2013; Korthuis et al., 2012).  Although HCV treatment 
can be effective among injection drug users, assessment and uptake remain low (Grebely 
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et al., 2009).  Injection drug users may be wrought with actual or perceived 
stigmatization that keeps them from seeking care, including HCV testing (Jordan et al., 
2013).  In addition to the issue of injection drug use, African Americans are 
disproportionately affected by socioeconomic factors, lack of adequate health insurance, 
and high treatment costs, which affect their health and contribute to disparities in health 
care access and treatment, as demonstrated in their poorer outcomes and survival of HCV 
infection (Melia at al., 2011).   
By 2019, the direct medical costs of treating persons with chronic HCV infection 
are projected to exceed $10.7 billion; the societal cost from premature death is estimated 
at $54.2 billion (Wong, McQuillan, McHutchison, & Poynard, 2000).  From the years 
2008 to 2011, pivotal clinical trials introducing novel direct-acting antivirals (DAAs) for 
the treatment of HCV infection were made available in the United States, followed by the 
Food and Drug Administration’s approval of two new DAAs, telaprevir and boceprevir, 
in May 2011.  Prior to 2008, the treatment for HCV infection had remained unchanged 
for 13 years.  Newer treatment options have demonstrated improved response rates for 
African Americans (Burton et al., 2012).  As a result, it is even more imperative that the 
health disparities impeding the care and treatment of HCV-infected African Americans 
are overcome with earlier intervention to reduce costs and improve outcomes.  Because 
HCV is a major health problem in the United States and significant health disparities 
affect HCV-infected African Americans, it is important to determine whether the 
introduction of newer treatment options with better response rates has improved both 
health care seeking behavior and provider responses for this population.  
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Problem Statement 
There are disparities in access to care and treatment affecting the African 
American population that are demonstrated in this population’s outcomes and survival of 
hepatitis C virus (HCV) infection (Artinyan et al., 2010; Davila & El-Serag, 2006; Jan et 
al., 2012).  Rates of HCV infection and HCV-related mortality are twice as high for 
African Americans as compared to non-Hispanic Whites (Saab et al., 2014).  Disparities 
also exist for HCV-infected African Americans due to disproportionately low 
socioeconomic status indicators (e.g., income and education); greater risk for and burden 
of disease; and insufficient access to, delivery of, and quality of health care (Artinyan et 
al., 2010; Davila & El-Serag, 2006; Sloane, Chen, & Howell, 2006; Tohme, Xing, Liao, 
& Holmberg, 2013).  Beginning in 2008, pivotal clinical trials introducing novel direct-
acting antivirals (DAAs) for the treatment of HCV infection were made available in the 
United States; in May 2011, the Food and Drug Administration approved two new DAAs, 
telaprevir and boceprevir.  Prior to 2008, the standard of care for HCV infection had 
remained the same for 13 years.  As a result, no previous studies have examined the 
health care seeking behavior and provider responses associated with HCV-positive 
African Americans since the introduction of newer treatment options.  
Purpose of the Study 
 In this quantitative study, I used data from the 2005-2012 NHANES datasets to 
determine whether the seeking of health care by African Americans who are HCV-
positive, and the offering of treatment by providers to African Americans who are HCV-
positive, had improved since 2008 following the introduction of new treatment options.  
The independent variable was HCV-positive persons who completed the 2005-2012 
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NHANES Hepatitis C Follow-Up Questionnaire (HCQ).  The dependent variables were 
the health care seeking behavior of HCV-positive persons and provider responses to 
HCV-positive persons and were represented by 10 questions from the NHANES 
Hepatitis C Follow-Up Questionnaire (HCQ). 
Research Questions and Hypotheses 
Two research questions guided this research.  The questions, including null and 
alternative hypotheses, were as follows: 
Research Question 1 
Has the seeking of health care, as defined by self-report HCQ responses, by HCV-
positive African Americans improved since 2008 following the introduction of new 
treatment options as compared to other HCV-positive racial/ethnic groups? 
Null hypothesis (H01): Seeking of health care, as defined by self-report HCQ 
responses, by HCV-positive African Americans has not improved since 2008 following 
the introduction of new treatment options as compared to other HCV-positive 
racial/ethnic groups. 
Alternative hypothesis (Ha1):  Seeking of health care, as defined by self-report 
HCQ responses, by HCV-positive African Americans has improved since 2008 following 
the introduction of new treatment options as compared to other HCV-positive 
racial/ethnic groups. 
Research Question 2 
Has the response from health care providers, as defined by self-report HCQ 
responses, to HCV-positive African Americans improved since 2008 following the 
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introduction of new treatment options as compared to other HCV-positive racial/ethnic 
groups? 
Null hypothesis (H02): The response from health care providers, as defined by 
self-report HCQ responses, to HCV-positive African Americans has not improved since 
2008 following the introduction of new treatment options as compared to other HCV-
positive racial/ethnic groups. 
Alternative hypothesis (Ha2): The response from health care providers, as defined 
by self-report HCQ responses, to HCV-positive African Americans has improved since 
2008 following the introduction of new treatment options as compared to other HCV-
positive racial/ethnic groups. 
Theoretical Framework for the Study 
The theory of reasoned action (TRA) was developed by Ajzen and Fishbein in 
1980, and evolved out of the expectancy value models in an attempt to understand the 
incongruity between attitude and behavior (Ajzen, 1991).  The TRA indicates that the 
intention to perform a behavior is a function of attitudes toward engaging in the behavior 
and perceived normative pressure to perform the behavior (Glanz, Rimer, & Viswanath, 
2008).  Therefore, performing a behavior is a function of a person’s intentions, which 
represents a combination of the person’s own attitudes toward the behavior and his or her 
subjective norms (Linke, Robinson, & Pekmezi, 2013).  By understanding a person’s 
attitude toward a health behavior (including the consequences of the health behavior), 
and what the person believes other people, especially influential people, would expect 
him or her to do, one can have an impact on whether the individual will seek medical care.   
It has been demonstrated that TRA is most useful in predicting behaviors under 
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volitional or perceived control; however, as discovered later on by Azjen and Fishbein, 
some behaviors are not entirely within an individual’s control (Azjen, 1991; Linke et al., 
2013).  In an attempt to better predict health behaviors, the theory of planned behavior 
(TPB) was also incorporated into the theoretical framework (Ajzen, 1991).  The TPB 
adds a construct called perceived behavioral control, which is defined as individuals’ 
perceptions of their ability to perform a given behavior (Ajzen, 1991).  This theory 
introduces an individual’s control beliefs, which are defined as (a) the presence or 
absence of perceived facilitators and barriers associated with a given behavior and (b) the 
impact of these facilitators and barriers (Linke et al., 2013).  
TRA and TPB were applied in the effort to determine health-seeking behaviors 
and influence behavioral change in the African American population infected with 
hepatitis C with regard to medical care access, follow-up, and treatment.  In this research, 
I attempted to determine whether the influence of newer drug treatments had improved 
health-seeking behavior and provider responses for African Americans infected with 
hepatitis C.  In its focus on real-world application, this study may serve to promote action 
on attitudes about HCV risk reduction, response to social norms (in the African American 
community), and intentions to change risky behaviors (e.g., intravenous drug use, risky 
sex practices) (Kiragu & Pulerwitz, 1999). 
Nature of the Study 
This study was a quantitative assessment that used secondary data from the 
National Health and Nutrition Examination Survey (NHANES) and Hepatitis C Follow-
Up Questionnaire (HCQ) for the following time periods: (a) 2005-2008 (before the 
introduction of new treatment options) and (b) 2009-2012 (during and after the 
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introduction of new treatment options).  Both surveys used a Likert-type format and 
collected relevant information from respondents that included sociodemographic 
information, health insurance status, drug use, health care seeking behavior, and provider 
responses.  Using the NHANES datasets, I conducted analyses of categorical variables 
that included age, gender, race, education, poverty index, health insurance status, and 
history of illegal injection drug use to provide descriptive statistics.  The independent 
variable consisted of all participants who tested positive for hepatitis C and completed the 
HCQ.  The dependent variables, health care seeking behavior and provider responses, 
were assessed through a total of 10 HCQ questions. Using the 2005-2012 HCQ datasets, I 
conducted statistical analyses of 10 survey questions using chi-square for frequencies and 
Fisher’s exact where applicable (e.g., small cell sizes) to examine all participants by 
racial/ethnic group in two time periods: 2005-2008 and 2009-2012 (Field, 2013).   
The study population was composed of 2005-2012 NHANES survey participants 
6 years of age or older who tested positive for hepatitis C (anti-HCV) and who also 
completed a Hepatitis C Follow-Up Questionnaire (HCQ) over the telephone.  All four 
NHANES 2-year datasets from 2005 to 2012 provided all the relevant questionnaires and 
variables necessary to conduct the research.  The NHANES collates nationally 
representative data on the health and nutritional status of the noninstitutionalized civilian 
population of the United States (Centers for Disease Control and Prevention, 2013a).  
NHANES uses a stratified and multistage probability sampling design and collects 
information from persons using standardized household interviews, physical 
examinations, and testing of biologic samples; the data are published in 2-year cycles 
(Ditah et al., 2014).  Data were collected according to NHANES procedures (Protocol 
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#2005-06, Protocol #2011-17), which were approved by the Ethics Review Board of the 
National Center for Health Statistics Research (Centers for Disease Control and 
Prevention, 2012b).  I describe the survey population and data collection methods in 
detail in Chapter 3. 
Operational Definitions 
 The following terms and phrases are defined as used in the present study. 
Hepatitis C antibody positive confirmed: hepatitis C antibody (anti-HCV) positive 
is a value that is calculated on all examinees 6 years or older by a serum specimen with 
laboratory testing as follows: Samples testing positive for anti-HCV by the screening test 
are tested in the confirmatory RIBA assay for antibody to Hepatitis C virus; samples with 
a positive RIBA result are reported as confirmed positive for antibody to HCV (Centers 
for Disease Control and Prevention, 2012c).  Samples with a negative RIBA result are 
reported as negative for antibody to HCV.  Samples with indeterminate RIBA results are 
tested for HCV-RNA (Centers for Disease Control and Prevention, 2012d). 
HCV-positive: This term is defined as applying to those NHANES participants 
who tested positive for antibody to HCV (anti-HCV), as well as to participants with 
indeterminate anti-HCV results who tested positive for HCV-RNA for survey years 
2005-2012 (Denniston, Klevens, McQuillan, & Jiles, 2012). 
Assumptions 
 Assumptions are factors that can potentially influence a study, but for which no 
hard data exist (Simon, 2011).  The assumptions, although not controlled for, are 
considered probably true and necessary; if they were absent, the study would become 
irrelevant (Simon, 2011).  
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This study was based on the following assumptions: 
• All study participants met NHANES eligibility. 
• All NHANES surveys and questionnaires were administered according to the 
survey protocol. 
• All study participants answered the NHANES survey truthfully. 
• All laboratory samples were collected, handled, and analyzed according to 
laboratory protocols. 
• All data downloaded from the CDC website were current and correct and have 
been handled and stored according to accepted data-management practices. 
Scope and Delimitations 
The scope of this study was the 2005-2012 NHANES study populations; the 
sample population used for the study was defined as consisting of individuals 6 years of 
age or older who were anti-HCV positive and completed the Hepatitis C Follow-Up 
Questionnaire (HCQ).  The NHANES total population for the time period 2005-2012 
equaled 40,790 persons.  For this same time period, a total of 394 (1.3%) out of 29,752 
serum samples tested positive for anti-HCV antibody (Centers for Disease Control and 
Prevention, 2013a).  One hundred thirty-two (33%) of the 394 anti-HCV positive 
individuals completed the HCQ.  Data for the 2005-2012 NHANES surveys were 
collected from January 2005 through December 2012.  Although NHANES provides a 
representative sample of the U.S. population, the National Center for Health Statistics 
analytic guidelines recommend combining HCQ data with other cycles when doing 
analysis and indicate that data from HCQs should not be used with sample weights to 
make national estimates due to small sample size and a response rate below 50% (Centers 
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for Disease Control and Prevention, 2012c).  The study was bound by the characteristics 
of the 2005-2012 NHANES study populations. The study did not analyze respondents 
who refused to complete the HCQ phone interview after being notified of an HCV 
positive test result, or respondents for whom data were missing.  
Limitations 
The NHANES variables were derived from self-report of the respondent; as a 
result, the potential exists for the variables to be affected by recall bias or 
misunderstanding of the question (Centers for Disease Control and Prevention, 2012e).  
The HCQ has a nonresponse bias that needs to be assessed and reported, and any 
information on reasons for missing data should be presented (Perlin, 2003).  The sample 
of HCV-positive participants was small and cannot be generalized to the U.S. population.  
The independent variable, serum anti-HCV antibody level, was subject to measurement 
variation, as well as to examiner effects (Centers for Disease Control and Prevention, 
2012e).  To address these limitations, public health and scientific communities reviewed 
the NHANES protocols (Centers for Disease Control and Prevention, 2013b).  Field staff 
interviewers are involved in comprehensive training and retraining on an annual basis; 
quality control measures are also implemented with interviewer monitoring, as well as 
data collection processes and systems (Centers for Disease Control and Prevention, 
2013b).  Another analytic limitation of the NHANES sample is that it was selected from a 
relatively small number of sampling units (PSUs) or counties, which may introduce a 
higher level of uncertainty in the annual estimates (Perlin, 2003).  The computation of 2-
year datasets is preferred to decrease variability in annual estimates.  
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Significance of the Study 
The aim of this research was to determine whether health care seeking behavior 
and provider responses for HCV-positive African Americans have improved since 2008 
with the introduction of newer treatment options as compared to other HCV-positive 
racial/ethnic groups.  Given that the African American population has the highest 
prevalence of HCV infection in the United States, it is important to understand the health 
disparities that make it difficult to identify and prevent transmission of this deadly virus 
within African American communities.  There are gaps that need further investigation in 
order to enable understanding of the “access to care” element for the African American 
population; in other words, more information is needed to answer the following 
questions: “What percentage of the population that has been diagnosed with HCV has 
medical insurance and is seeking health care for HCV?”  “Where is the misstep when it 
comes to the care of this population?”  “Is it with the providers’ responses and treatment 
decisions, or is it with the population who, although they have medical insurance, are not 
seeking medical attention; or, on the other hand, do not have medical insurance and are 
not seeking medical attention?”  
HCV infection remains a critical public health challenge in the African American 
population.  African Americans are most at risk of infection and transmission due to 
illegal injection drug use behavior, in addition to worse health outcomes including 
increased morbidity and mortality.  In order to reduce overall HCV prevalence at the 
population level, promotion, education, and intervention strategies need to be based in 
African American communities.  The findings add to the body of research on health 
inequities with minority and underserved populations, including populations with lower 
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socioeconomic status in general.  Positive social change may occur in the way of 
reinforcing awareness of the risks of HCV infection, reducing provider bias, and 
introducing resources into the African American communities to allow better access to 
care for this population, improving outcomes and removing barriers to care.  The findings 
may introduce implications for future research to assess why African Americans do not 
access health care and potential solutions to those barriers, perhaps with a community-
based participatory approach formed by an integrated group of health care providers, 
community members, patients, families, and other key stakeholders. 
Summary 
HCV infection is a serious health problem within the African American 
community.  There are disparities with access to care and treatment for the HCV-positive 
African American population that result in poorer morbidity and mortality (Artinyan et 
al., 2010; Davila & El-Serag, 2006; Jan et al., 2012).  Disparities also exist for HCV-
infected African Americans due to disproportionately lower socioeconomic status, greater 
risk for and burden of disease, and insufficient access to, delivery of, and quality of 
health care (Artinyan et al., 2010; Davila & El-Serag, 2006; Sloane, Chen, & Howell, 
2006; Tohme, Xing, Liao, & Holmberg, 2013).  Newer treatment options have improved 
cure rates for all HCV-infected populations.  This study addressed the following 
question: Has the health care seeking behavior and provider responses for HCV-positive 
African Americans improved since 2008 with the introduction of newer treatment options 
as compared to other HCV-positive racial/ethnic groups?  The study’s findings may guide 
public health policies and health care providers in targeting groups that are most at risk. 
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In Chapter 2, I provide background information on the results of previous 
research related to HCV infection, based on an extensive literature search.  I examine the 
role of HCV infection in the United States, and its epidemiology, risk factors, morbidity, 
mortality, sociodemographic factors, economic burden, and treatment.  I also specifically 
examine HCV infection in the African American population, including epidemiology, 
risk factors, clinical features, and access to care and treatment. 
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Chapter 2: Literature Review 
Introduction 
There are disparities in access to medical care and treatment for the African 
American population that are demonstrated in their outcomes and survival of hepatitis C 
virus (HCV) infection (Artinyan et al., 2010; Davila & El-Serag, 2006; Jan et al., 2012).  
The rates of HCV infection and HCV-related mortality are twice as high for African 
Americans as compared to non-Hispanic Whites (Saab et al., 2014).  Disparities also exist 
for HCV-infected African Americans due to disproportionately lower socioeconomic 
status indicators (e.g., income and education); greater risk for and burden of disease; and 
insufficient access to, delivery of, and quality of health care (Artinyan et al., 2010; Davila 
& El-Serag, 2006; Sloane et al., 2006; Tohme, Xing, Liao, & Holmberg, 2013).   
In 2008, pivotal clinical trials introducing novel direct-acting antivirals (DAAs) 
for the treatment of HCV infection were made available in the United States, followed by 
the Food and Drug Administration’s approval in 2011 of two new DAAs, telaprevir and 
boceprevir.  Prior to 2008, the treatment for HCV infection had remained the same for 13 
years.  The new treatment regimens using DAAs with pegylated interferon and ribavirin 
have improved sustained viral response (SVR) rates for the HCV-infected African 
American population as compared to the previous non-DAA therapies (50-62% versus 
19-21%, respectively; Burton et al., 2012).  The purpose of this research was to determine 
whether the seeking of health care by HCV-positive African Americans, and the 
responses from health care providers to HCV-positive African Americans, had improved 
since 2008 following the introduction of new treatment options, as compared to other 
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HCV-positive racial/ethnic groups, using survey datasets from the National Health and 
Nutrition Examination Survey (NHANES).   
This literature review addresses HCV infection in the United States, and its 
epidemiology, risk factors, morbidity, mortality, sociodemographic factors, economic 
burden, and treatment.  This review also specifically addresses HCV infection in the 
African American population, including epidemiology, risk factors, clinical features, and 
access to care and treatment. 
Literature Search Strategy 
 Within the Walden University Library, I used the following research databases to 
conduct this literature review: MEDLINE, PubMed, ScienceDirect, Cochrane Reviews, 
and Academic Search Complete.  Within the UCLA Library, I used the ProQuest 
research database to conduct this literature review.  Search terms included African 
American, hepatitis C, United States, access to care, disparities, epidemiology, race, risk 
factors, treatment, socioeconomic status, injection drug use, and health seeking behavior.  
I did not limit the search by year of publication and searched all databases up to the 
present date.  In addition, I located additional governmental and medical information 
resources by using Google. 
 I identified a total of 175 publications from the years 1990 to 2015 for review, and 
I included all publications based on their relevance to the present study.  The articles 
selected were grouped into the following categories as they related to hepatitis C in the 
United States: epidemiology, liver cancer/transplant, burden and/or cost, treatment 
response and/or uptake, injection drug use, African American and/or race, and health 
seeking behavior.  The majority of the cited references were published in peer-reviewed, 
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scientific journals.  Almost all of the selected studies took place in the United States, with 
the exception of a few international review articles that included the United States. 
Theoretical Framework 
The theory of reasoned action (TRA) and theory of planned behavior (TPB) were 
developed in an effort to explain why people behave in the way they do and to understand 
the decisions and actions that make a person change an unhealthy behavior to a healthier 
behavior (Lezin, 2015).  Both are useful to those wishing to assess and better understand 
health care seeking behaviors, as well as to influence behavioral change in the African 
American population infected with HCV with regard to medical care access, follow-up, 
and treatment.  Through this research, I attempted to assess and understand whether the 
influence of newer drug treatments had improved access to care for African Americans 
infected with HCV.  Further, I hoped to form a bridge from this research to real-world 
application by promoting action concerning attitudes about HCV risk reduction, response 
to social norms (in the African American community), and intentions to change risky 
behaviors (e.g., intravenous drug use, risky sex practices; Kiragu & Pulerwitz, 1999). 
Theory of Reasoned Action 
TRA centers on a person’s intention to behave in a certain way.  An intention is a 
“plan or a likelihood that someone will behave in a particular way in specific situations,” 
whether this happens or not (Glanz et al., 2008, p. xx).  For example, a person infected 
with HCV may be thinking about seeking follow-up care and/or treatment, but may or 
may not actually follow through on that intent.  To understand behavioral intent, TRA 
may be used to examine the person’s (or population’s) attitudes toward the behavior, as 
well as subjective norms (Linke et al., 2013).  Subjective norms are influenced by how a 
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person believes those around him or her will think about the behavior in question; these 
people are generally influential in some way and may include parents, friends, partners, 
or a pastor.  Jordan and colleagues (2013) explored the perceptions of drug users and 
found that leveraging support from peers may be a valuable way to engage injection drug 
users in HCV care.   
As discussed previously, people’s attitudes and norms decide their intentions, 
which, in turn, are the main drivers of behavior (Lezin, 2015).  People’s attitudes toward 
a particular behavior are influenced by their beliefs about the outcome of the behavior 
and their evaluation of the potential outcome.  Mehta and colleagues (2008) found that 
the majority of HCV-infected injection drug users reported that a belief that treatment 
would not cure them.  African American injection drug users from another study 
perceived treatment as unimportant because they lacked symptoms, providers minimized 
the severity of the disease, or providers did not recommend treatment (Jordan et al., 
2013).  The more there is an understanding of a person’s or population’s attitudes and 
norms, the greater the ability to introduce more precise and successful interventions.  
Theory of Planned Behavior 
To enhance the prediction process concerning a person’s health behaviors, TPB 
can also be incorporated into research.  TPB brings with it a paradigm called perceived 
behavioral control, which is defined as the extent to which people believe that they do or 
do not possess the necessary skills and resources to overcome any difficulties in engaging 
in a behavior (Ajzen, 1991).  TPB involves consideration of volitional control as a 
variable.  Volitional control, by definition, requires having the resources, opportunity, 
and support available to perform a specific behavior (Ajzen, 1991).  In the published 
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literature, several studies have demonstrated that health disparities prevent these elements 
from being available for African Americans infected with HCV and that therefore, this 
population lacks the ability or behavior to seek and receive adequate and proper care 
(Artinyan et al., 2010; Backus et al., 2014; Ditah et al., 2014; Jan et al., 2012; Jordan et 
al., 2013; Mathur et al., 2010). 
Hepatitis C Virus Infection in the United States 
The hepatitis C virus (HCV) was discovered by researchers in 1989; prior to that 
time, it was known as non-A, non-B hepatitis (Lindenbach & Rice, 2005).  HCV consists 
of a 9,600 nucleotide genome-single polyprotein; there are seven genotypes that predict 
treatment response, with genotype 1 (harder to treat) accounting for approximately 70% 
of infections in the United States (Ward, 2014).  HCV is the most common blood-borne 
infection in the United States (Ditah et al., 2014).  Diagnosis of HCV is confirmed by two 
tests: (a) anti-HCV antibody test and (b) HCV RNA test.  If both tests are positive, a 
person is HCV infected and requires a medical evaluation for active infection and liver 
disease (Centers for Disease Control and Prevention, 2015a; Gretch, 1997).   
Prevalence of HCV infection in the United States has been estimated from 2.7 to 
3.5 million persons, which equals 1.0-1.4% of the population (Denniston et al., 2014; 
Ditah et al., 2014).  Since the introduction of effective screening of blood product donors 
in the 1990s, the incidence of new infections has declined dramatically; in 2012, only 
21,870 persons were estimated to have acquired new HCV infections (Centers for 
Disease Control and Prevention, 2015b).  Among all persons who initially acquire HCV, 
20-25% will clear the virus naturally and 75-80% will develop chronic HCV (Centers for 
Disease Control and Prevention, 2012a). Within the first 20 years, 20% of persons with 
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chronic HCV will develop cirrhosis (permanent scarring of the liver); one to seven will 
develop liver cancer yearly (Centers for Disease Control and Prevention, 2012a; Kanda et 
al., 2013). 
Risk Factors 
The risk factors for acquiring HCV in the United States include injection drug use, 
sexual transmission, perinatal transmission, occupational exposures among health 
workers, incarceration, intranasal drug use, tattooing, receipt of solid organ 
transplantation, and other percutaneous exposures, including a history of receiving a 
blood product transfusion prior to 1992, hemophilia with receipt of factor concentrates 
made before 1987, and hemodialysis  (U.S. Preventive Services Task Force, 2014).  In 
addition, adults born between 1945 and 1965 have been identified as a high-risk group 
because they are more likely to have received blood transfusions before 1992 or to have a 
history of other risk factors for exposure decades earlier (U.S. Preventive Services Task 
Force, 2014).  In at least 21% of HCV-positive individuals, no risk factors for infection 
are identified (U.S. Preventive Services Task Force, 2014).   
Injection drug use. Injection drug use is the most prevalent risk behavior and 
primary driver for HCV virus transmission (Centers for Disease Control and Prevention, 
2015b).  The mortality rate for injection drug users (IDUs) who are infected with HCV is 
1 to 2 per 100 person years (Degenhardt, Hall, & Warner-Smith, 2006).  Researchers 
have found that IDUs account for 60% of newly diagnosed HCV cases (Jordan et al., 
2013; Nelson et al., 2011).  Prevalence of HCV among IDUs is 65% and greater than 
80% among long-term IDUs (Hagan et al., 2008).  A global systematic review of over 
1,100 data sources found that approximately 73% of all IDUs in the United States carry 
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chronic HCV infection (Nelson et al., 2011).  In a meta-analysis of HCV-infected IDUs, 
researchers found that the 20-year cirrhosis prevalence was 15% (John-Baptiste et al., 
2010).  Researchers have identified the following sociodemographic characteristics to be 
associated with IDUs: a lack of health insurance, transportation problems, insufficient 
disposable income to cover health care costs, residing in low medical coverage areas, an 
education level of high school or less, low income level, homelessness, and 
unemployment (Oche, 2014).  In addition, researchers have found that IDUs who engage 
in syringe/needle sharing behavior have lower educational attainment (Korthuis et al., 
2012). Although HCV treatment can be effective among IDUs, assessment and uptake 
remain low (Grebely et al., 2009).  Injection drug users may be wrought with experiences 
of actual or perceived stigmatization that keep them from seeking care, including HCV 
testing (Jordan et al., 2013).  Researchers have found that once diagnosed, many IDUs do 
not receive clear messages about their HCV infection and the follow-up needed, which 
has also resulted in mistrust of health care providers (Jordan et al., 2013). 
 Sexual transmission. Although sexual transmission of HCV in the general 
population remains controversial, there is evidence that HCV transmission occurs 
through sexual contact, especially among HIV-positive men who have sex with men 
(MSM; Bradshaw, Matthews, & Danta, 2013; Tohme & Holmberg, 2010).  Heterosexual 
transmission of HCV is estimated to occur at a rate of 0-0.6% per year (Bradshaw et al., 
2013).  Researchers have found evidence suggesting that there is no increased risk of 
sexual transmission of HCV among heterosexual couples in regular relationships (Tohme 
& Holmberg, 2010).  On the contrary, a heterosexual person who has multiple sexual 
partners has a 2- to 3-fold risk of acquiring HCV infection through sexual transmission 
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(Tohme & Holmberg, 2010).  Women who are HIV positive or have other sexually 
transmitted diseases (STDs) have up to a 4-fold risk of acquiring HCV infection (Tohme 
& Holmberg, 2010).  The risk is greatest for sexual contact between HIV-positive MSM 
(aOR 4.1-5.7), and this risk increases with high-risk sexual behavior and the presence of 
genital ulcerative disease (Tohme & Holmberg, 2010).   
 Perinatal transmission. Chronic HCV infection is the most common form in 
pregnant women; acute hepatitis C is very rare during pregnancy (Floreani, 2013).  
Chronic HCV infection does not have an adverse effect on either the course of the 
pregnancy or the newborn infant’s birth weight; conversely, pregnancy does not induce a 
negative impact on a woman’s HCV infection as well (Floreani, 2013).  The overall rate 
of mother-to-child transmission is 3 to 5%, with the most important risk factors for 
vertical transmission including high viral load, HIV coinfection, and invasive procedures 
(Floreani, 2013).  Viral clearance prior to pregnancy is the goal to reduce vertical 
transmission of HCV (Floreani, 2013).  
Occupational exposures among health workers. For workers who are exposed, 
there is currently no recommended prophylaxis for HCV (Zingman, 2013).  The risk of 
transmission of HCV from an occupational exposure of needlestick is 1.8% (Zingman, 
2013).  The risk of transmission from HCV from a single mucous membrane exposure is 
negligible (Zingman, 2013).   
Incarceration. Approximately 2.2 million people in the United States are 
incarcerated, and up to 1 in 3 carries HCV infection (Centers for Disease Control and 
Prevention, 2014a). The prevalence of chronic HCV infection among prison inmates 
ranges as high as 12% to 35% (Centers for Disease Control and Prevention, 2014a).  
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HCV infection in this setting is primarily associated with a history of injection drug use.  
Transmission in this setting may result from sharing equipment used for injecting drugs, 
tattooing, and piercing with other people who are already infected; sexual transmission is 
a component as well (Centers for Disease Control and Prevention, 2014a).   
Intranasal drug use. Researchers have demonstrated that blood and HCV RNA 
are present in nasal secretions and drug-sniffing devices of HCV-infected intranasal drug 
users (Aaron et al., 2008). In addition, researchers have suggested that with episodes of 
active drug sniffing, HCV will be present with greater frequency and quantity, which 
may exacerbate discharge of nasal fluids and blood (Aaron et al., 2008).  Little is known 
about the quantity of virus required for transmission, but researchers have demonstrated 
that HCV can remain viable on environmental surfaces for up to 16 hours (Krawczynski 
et al., 2003).  
Tattooing. Researchers who conducted a systematic review of the literature over 
an 18-year period (1994-2011) found no definitive evidence of transmission of HCV 
infection when sterile equipment or professional tattoo parlors were used (Tohme & 
Holmberg, 2012).  They did find that the risk of HCV transmission was 2- to 3.5-fold 
higher when tattoos were applied in nonprofessional settings including prisons or by 
friends (Tohme & Holmberg, 2012). 
Solid organ transplant recipient.  HCV infection is the leading indication for 
liver transplantation worldwide (Levitsky et al., 2013).  Among kidney transplant 
recipients, 10-year survival is approximately 15% lower in HCV-positive compared to 
HCV-negative individuals (Levitsky et al., 2013).  Other organ transplants that were 
examined either have no long-term data (heart, small bowel, and pancreas) or have shown 
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no difference in survival between HCV-positive versus HCV-negative recipients (lung; 
Levitsky et al., 2013).   
Percutaneous exposures. Due to the implementation of blood product screening 
in the early 1990s, the prevalence of percutaneous exposures has greatly diminished.  
Although HCV infection is an independent risk factor for mortality in hemodialysis 
patients, researchers found the prevalence in hemodialysis units to be 14% and a 
seroconversion rate of 2.5% per 100 patient-years (Fissell et al., 2004).   
Due to donor selection and testing improvements, the blood supply in the United 
States has become immensely safer (Zou, Stramer, & Dodd, 2012).  Researchers who 
examined donor risk found the HCV incidence rate among repeat donors to be in the 
range of 2.16 and 2.98 per 100,000 person-years; the residual risk of HCV virus among 
all allogeneic donations was found to be below 1 per 1 million donations (Zou et al., 
2012).   
A majority of the cases of HCV infection in persons with hemophilia are 
presumed to result from blood transfusions before sensitive screening tests were 
introduced in 1992 (Orman & Fried, 2012).  Persons with hemophilia acquire HCV 
infection at a lower mean age of 9-10 years relative to other groups at risk (Orman & 
Fried, 2012).  Researchers have reported the prevalence of HCV infection among persons 
with sickle-cell disease ranging from 10-20% and among persons with thalassemia at 
35% (Orman & Fried, 2012).   
Born during 1945-1965. Seventy-five percent of all persons living with HCV 
infection and 75% of HCV-associated deaths are attributed to those who were born 
during the years 1945 to 1965 (Centers for Disease Control and Prevention, 2015a).  The 
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prevalence of HCV antibodies in this cohort is approximately 3%, which is 5 times 
higher than in other age cohorts (Centers for Disease Control and Prevention, 2015a).  As 
a result, the Centers for Disease Control and Prevention (2015a) have added the birth 
cohort of 1945-1965 to the HCV one-time screening recommendations. 
Morbidity and Mortality 
HCV is the cause of death or contributing cause of death in approximately 15,000 
people per year with more than 70% of deaths in people ages 45 to 64 years old (Centers 
for Disease Control and Prevention, 2015a).  Since 2007, mortality among HCV-infected 
persons continues to exceed deaths from HIV/AIDS in the United States (Centers for 
Disease Control and Prevention, 2015a).  HCV-infected individuals have mortality rates 
up to 3 times higher than those in the general population; in addition, they carry an 8- to 
12-year reduction in overall life expectancy (Jacobson, Cacoub, Dal Maso, Harrison, & 
Younossi, 2010).  Major factors associated with an increased risk of death include 
chronic liver disease, co-infection with hepatitis B or HIV, alcohol-related conditions, 
and minority status (Centers for Disease Control and Prevention, 2015a).  End-stage liver 
disease and hepatocellular carcinoma are significant causes of death in this population, 
with liver transplantation as the only therapeutic option for many of these patients 
(Klevens, Hu, Jiles, & Holmberg, 2012; Layden et al., 2012).  In 2011, chronic liver 
disease, including cirrhosis, was the 12th leading cause of death in the United States, and 
viral hepatitis-associated death rates were highest among persons infected with HCV 
(Centers for Disease Control and Prevention, 2015a).  For those who do not succumb to 
cirrhosis, this disease is still wrought with other physical and psychological 
manifestations which can include fatigue, vasculitis, arthralgias, neuropathy, 
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lymphoproliferative malignancies, insulin resistance, type 2 diabetes, depression, and 
cognitive impairment (Jacobson et al., 2010).  These extrahepatic manifestations have 
contributed to approximately 15% of all HCV-related hospitalizations (Moorman, 2013).  
Liver transplantation. HCV infection is the leading indication for liver 
transplantation.  Post-transplantation HCV recurrence is universal and the rate is 
accelerated in the new graft compared to pre-transplantation (Levitsky et al., 2013).  Post-
transplantation recipients demonstrate a recurrence of HCV infection within the first 5 
years (Levitsky et al., 2009).  Overall 5-year patient survival is 65%, and 5-year graft 
survival is 60% in HCV-infected recipients (Levitsky et al., 2009).  With the onset of 
recurrent HCV cirrhosis comes a 50% incidence of liver decompensation within one year, 
which results in a 1- and 4-year patient survival of only 66% and 33%, respectively 
(Brown, 2005).   
Sociodemographic Characteristics 
 There are sociodemographic disparities that exist with the HCV infected 
population.  Researchers examined the National Health and Nutrition Examination 
Survey (NHANES) data over an 8-year period (2003-2010) and found that almost one-
half of chronic HCV infected persons were between the ages of 40-59 years, and 64% 
were male (Denniston et al., 2014).  In addition, if a person had less than a high school 
education/GED (< 12th grade), they were twice as likely to have chronic HCV infection 
(OR 2.0, 1.2-3.3); if a person had a family income less than two times the poverty level 
(equals @ $22,000-52,000 based on household size), they were almost four times as 
likely to have chronic HCV infection (OR 3.7, 2.6-5.3; Denniston et al., 2014).  On the 
contrary, using the same data, researchers found the percentage of current, unresolved 
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HCV infection was lowest among those with a college education (57.3%; Liu, Holmberg, 
Kamili, & Xu, 2014).   
Researchers who examined survival of patients with hepatocellular carcinoma 
found that lower income patients continue to have the worst survival as compared to 
middle- and high-income patients (Artinyan et al., 2010).  Inconsistencies in access to 
appropriate care as well as differences in underlying disease are thought to be 
contributors (Artinyan et al., 2010).  Researchers who examined liver cirrhosis using the 
NHANES data over a 12-year period (1999-2010) found the prevalence to be higher in 
those living below the poverty level, and those with less than a high school education 
(Scaglione et al., 2014).  The goals of HCV infection as a major public health challenge 
include increasing both the proportion of persons who get tested, and the proportion of 
persons who test positive receiving the appropriate referral to care and treatment (Centers 
for Disease Control and Prevention, 2015a).  
Economic Burden 
The excessive burden of high treatment costs for managing HCV and its sequelae 
not only impacts the patient, but also impacts private and government health care 
agencies (Jacobson et al, 2010).  Progressive liver disease and its associated health care 
costs can be avoided with early diagnosis and treatment of HCV infection.  Researchers 
have found that direct healthcare costs associated with chronic HCV infection increase in 
association with the progression of liver disease, and are highest in persons with end-
stage liver disease (Gordon et al., 2012).  By 2019, the direct medical costs of chronic 
HCV infection are projected to exceed $10.7 billion along with a societal impact from 
premature mortality estimated at $54.2 billion (Wong et al., 2000).  Researchers showed 
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that birth cohort screening of all patients born between 1945 and 1965 is cost-effective at 
a rate of $2,874 per case identified and can add between $15,700 and $35,700 per 
quality-adjusted life year (QALY) based on the type of HCV treatment provided (Rein et 
al., 2012). 
Treatment of HCV Infection 
 In 2011, the Food and Drug Administration approved two new direct-acting 
antivirals (DAAs) against HCV, telaprevir (TVR) and boceprevir (BOC), in combination 
with pegylated interferon and ribavirin (U.S. Food and Drug Administration, 2011).  In 
studies, the triple combination of TVR or BOC plus pegylated interferon and ribavirin 
have demonstrated sustained viral response (SVR) rates in treatment-naïve, genotype 1 
patients as high as 66% to 69% (Kanda et al., 2013).  Overall, SVR rates are lower in 
previous relapse, partial response, non-response, and relapse populations (Kanda et al., 
2013).  As of 2013, there is now a total of six second generation DAAs being used (alone 
or in combination) for the treatment of HCV infection (U.S. Food and Drug 
Administration, 2014).  In studies, high rates of SVR (89%-90%) have been 
demonstrated in treatment-naïve patients with second generation DAAs (Kohli, Shaffer, 
Sherman, & Kottilil, 2014).  
HCV Infection in African Americans 
African Americans account for 22% of persons infected with HCV in the United 
States (Fleckenstein, 2004).  The prevalence of chronic HCV infection in the African 
American population is 2-fold higher than the Hispanic and Caucasian populations (3% 
versus 1.3% and 1.5%, respectively; Kemmer & Neff, 2010).  Over a 10-year period, 
researchers found that African Americans carried the greatest burden of HCV infection; 
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during this same time period, there was also a 27.3% increase in the rate of HCV 
infection for this population (Centers for Disease Control and Prevention, 2015a; Ditah et 
al., 2014).  Researchers who examined the epidemiology of HCV infection using the 
NHANES datasets between the years 2001 and 2010 found that African Americans had a 
1.5- to 2-fold greater risk of having HCV infection versus all other ethnic groups (Ditah 
et al., 2014; Denniston et al., 2014).  In addition, HCV-infected African Americans are 
disproportionately affected when it comes to morbidity, mortality, access to care, quality 
of care, and treatment response.   
Hepatitis-C related chronic liver disease is a leading cause of death among 
African American persons 45 to 64 years of age (Centers for Disease Control and 
Prevention, 2012a).  Researchers have demonstrated that African Americans have poorer 
health outcomes including a two-fold higher rate of liver cancer, a two to three times 
higher rate of liver cancer-related mortality, and lower rates of survival from liver 
transplantation (Layden et al., 2012; Pearlman, 2006).  In addition, this population suffers 
from health disparities that lead to inadequate and inappropriate treatment and care.  
Researchers have found that risk factors associated with HCV-related liver disease 
morbidity and mortality include ethnicity, access to HCV therapy, and a favorable 
treatment response (Grebely & Dore, 2011).  
Injection Drug Use 
African Americans are substantially and persistently overrepresented among 
people diagnosed with injection-related health problems, including higher HCV rates as 
compared to non-Hispanic White injection drug users (IDUs; Amon et al., 2008).  
Between May 2005 and February 2006, the CDC’s National HIV Behavior Surveillance 
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System (NHBS) interviewed more than 10,000 IDUs; African Americans made up almost 
one-half (47.1%) of those who participated (Centers for Disease Control and Prevention, 
2009a).  In addition, results showed that during the preceding 12 months, one-third of 
African American participants reported sharing syringes or injection equipment (29.1% 
and 33.1%, respectively; Centers for Disease Control and Prevention, 2009a).  In addition, 
31.4% of African American IDUs reported never getting tested for HCV infection in their 
lifetime (Centers for Disease Control and Prevention, 2009a).  Data on the socioeconomic 
status of IDUs in the United States is difficult to find in the current literature.  
Researchers surveyed 600 IDUs in New York City and found that African Americans 
were less likely to attend a private medical office in the past year; whereas, those with 
higher income and health insurance coverage were more likely to attend a private medical 
office (Turner, Harripersaud, Crawford, Rivera, & Fuller, 2013).  The relationship 
between injection drug use and HCV transmission among the African American 
population is well established.  In four U.S. cities over a 10-year period (1994-2004), 
researchers found that although overall trend declined, the prevalence of HCV infection 
in the African American IDUs remained unchanged (Amon et al., 2008).  These same 
researchers also found that HCV antibody positive prevalence increases with age, number 
of years injecting, and intensity of injection drug use (Amon et al., 2008). 
Socioeconomic Status 
Low socioeconomic status and less education are often associated with high risk 
behaviors, including injection drug use, and thus, a higher risk of HCV infection (Ditah et 
al., 2014). African Americans are at greater risk for HCV infection due to a poorer 
socioeconomic status including poverty, lower employment rates and lack of education 
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(Estrada, 2005; Fuller et al., 2005; Galea & Vlahov, 2002).  In the United States, African 
Americans have one of the highest national poverty rates (25.8%); poverty rates of 20% 
or higher exist in 43 states for the African American population (Macartney, Bishaw, & 
Fontenot, 2013).  Even higher poverty rates exist for African Americans in both single 
male-headed households (27%), and single female-headed households (40%); this results 
in African American children being three times more likely to live in poverty than 
Caucasian children (Macartney et al., 2013).  Poverty can lead to early school dropout, 
loss of self-worth, and the uptake of illegal or socially unacceptable activities, such as 
injection drug use, which puts African Americans at risk for HCV infection (Estrada, 
2005).   
For the age group16 to 24 years old, as compared to all students combined, 
African Americans have higher rates of not being enrolled in school, and not earning a 
high school diploma (National Center for Education Statistics, 2011).  A researcher that 
examined the adverse effects from a poor socioeconomic status among the IDU 
population found that 64% of African American males had completed less than 12 years 
of school (Galea & Vlahov, 2002).  Other researchers found that the initiation of injection 
drug use was associated with neighborhood level factors including African American 
race, lower employment rates, and lower education levels (Fuller et al., 2005).  
Clinical Features 
 Of the 20-25% who spontaneously clear hepatitis C virus from their body, the rate 
is lowest among African Americans versus Caucasians and Hispanics (9% versus 27% 
and 31%, respectively) (Mir, Stepanova, Afendy, Kugelmas, & Younossi, 2012).  
Researchers have discovered that variation in genes involved in the immune response 
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may contribute to the ability of an individual to clear the hepatitis C virus (Thomas et al., 
2009).  Researchers conducted a genome-wide association study which identified a single 
nucleotide polymorphism of the IL28b gene; from this gene, there are three genotypes: 
C/C, C/T, and T/T (Ge et al., 2009).  Researchers examined these three genotypes and 
their influence on natural HCV clearance and found that African Americans carry a 
higher frequency of the IL28b T/T genotype, which is more strongly associated with 
lower rates of natural clearance of HCV versus the other two genotypes (Thomas et al., 
2009).  These findings help to explain some of the variability in spontaneous HCV 
clearance with African Americans leaving still yet more to be discovered with 
epidemiological, viral, and host factor associations.  
 Liver cancer.  HCV-infected persons are at risk for developing liver cancer after 
two or more decades of infection; those at greatest risk have cirrhosis or advanced 
fibrosis (de Oliveria Andrade et al., 2009).  Persons with HCV-related cirrhosis have a 2-
6% risk of developing liver cancer after two or more decades (de Oliveria Andrade et al., 
2009).  There is a 17-fold increased risk of developing liver cancer for HCV-infected 
persons compared to HCV-negative persons (de Oliveria Andrade et al., 2009).  The 5-
year overall survival of persons with liver cancer ranges from 6% to 7% (Artinyan et al., 
2010).   
Racial inequities in liver cancer outcomes have been observed (Davila & El-Serag, 
2006; Sloane et al., 2006).  African Americans have higher rates of liver cancer from 
HCV infection (Burton et al., 2012).  Researchers examined risk factors for liver cancer 
in persons with HCV-related cirrhosis and found that “African American race” was 
independently associated with the development of liver cancer in this cohort (Sarbah et 
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al., 2004).  Researchers examined trends in survival of liver cancer over forty years and 
discovered that African Americans have the worst survival, compared with all other 
ethnic subgroups (HR 1.66, 95% CI, 1.29-2.12, p < .001; Artinyan et al., 2010).  
Researchers who examined 3 national registries over a 21-year period found that, 
compared to Caucasians, African Americans had an 11% higher mortality risk, and the 
lowest 3-year survival from liver cancer (Davila & El-Serag, 2006). 
 Liver transplant.  Researchers examined racial/ethnic disparities in liver 
transplant patients and found that the transplant rate for African Americans was 
significantly lower versus Caucasians (Mathur, Schaubel, Gong, Guidinger, & Merion, 
2010).  Other researchers examined the race related differences during the first 2 years 
post liver transplantation and found a greater severity of HCV recurrence and fibrosis 
progression among African American recipients; in addition, a higher percentage of 
severe fibrosis and poorer patient survival was present in the African American 
recipient/White donor group (Layden et al., 2012).  
Access to Care and Treatment 
Disparities with access to care and treatment for the African American population 
are demonstrated in their outcomes and survival of HCV infection.  Using the NHANES 
data from 2003 to 2010, researchers found that African Americans carried the highest 
percentage (91.1%) of current, unresolved HCV infections (Liu et al., 2014).  In a broad 
population-based study using two national databases, researchers examined 40 years of 
liver cancer survival trends and found that both lower income patients and African 
Americans continued to have the worst survival rates (Artinyan et al., 2010).  Other 
researchers have shown similar findings in which health outcomes have not been 
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identical when it comes to race, with significantly poorer survival in African Americans; 
researchers have addressed these disparities by suggesting racial and health biases in the 
delivery of appropriate treatment  (Davila & El-Serag, 2006; Sloane et al., 2006).  
Researchers that examined liver cancer outcomes over a nine-year period in African 
Americans versus Caucasians in an inner-city urban setting found that African Americans 
were more likely to present with late stage liver disease (cirrhosis), and with a larger 
tumor size at time of cancer diagnosis (Jan et al., 2012).  This same African American 
cohort was also less likely to have private insurance, and a greater prevalence of IDUs 
(Jan et al., 2012).   
 Health-seeking behavior. With the African American population, themes that 
have emerged regarding barriers to health seeking behavior include socioeconomic status, 
lack of health insurance, language barriers, lack of awareness of the need for care, racism, 
discrimination, distrust of the medical establishment, and religion or spirituality 
(Cheatham, Barksdale, & Rodgers, 2008; Hewins-Maroney, Schumaker, & Williams, 
2005; Rooks, Wiltshire, Elder, Belue, & Gary, 2012).  Researchers who examined the 
source of information on health care used by African Americans in low-income 
households found that informal channels were preferred with over half (53.9%) using 
their family physician, and one-third (30.4%) using their family members (Spink & Cole, 
2001).  Lower socioeconomic status and minority groups are more likely to rely on 
interpersonal and non-medical sources for health information, health maintenance and 
treatment of illnesses (Rooks et al., 2012; Kontos, Emmons, Puleo, & Viswanath, 2011).  
Relying solely on health care provider interactions can be problematic as well since 
African Americans often report fewer participatory medical visits due to real or perceived 
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barriers of unfair treatment or mistrust (Blanchard, Nayar, & Lurie, 2007; Johnson, Roter, 
Powe, & Cooper, 2004).  Researchers found that as education level increases, the odds of 
seeking health information increases for all racial and ethnic groups including African 
Americans (Rooks et al., 2012).  Ethnic/racial minority groups with lower education 
levels may have disparities from low health literacy.  Low health literacy can result in 
communication challenges, limited understanding and input on a person’s care, and a 
withdrawal from accessing care due to embarrassment and/or masculinity issues (Rooks 
et al., 2012). 
An examination of the racial differences in HCV treatment eligibility found that 
African Americans are 36% less likely than Caucasians to receive treatment for HCV 
infection (Melia et al., 2011).  In addition, African Americans have co-morbidities that 
can impede their eligibility to receive treatment; they suffer from higher rates of 
neutropenia, anemia, diabetes, and renal dysfunction (Melia et al., 2011).  Overall, this 
introduces the paradox of African Americans carrying the greatest burden of HCV, and 
yet having lower treatment efficacy due to poorer response rates or ineligibility.  Along 
with the individual co-morbidities that impact low treatment rates, African Americans are 
also disproportionately affected by the lack of adequate health insurance, and high 
treatment costs which present barriers to care for this population (Melia et al., 2011).   
African Americans infected with HCV have significantly lower rates of SVR 
from treatment (Melia et al., 2011; Muir et al., 2004).  Part of this is attributed to 
evidence linking African Americans to carrying a high rate of IL28B T/T genotype, 
which is associated with lower interferon responsiveness resulting in treatment-induced 
HCV clearance, versus other genotypes (Thomas et al., 2009).  Persons who achieve SVR 
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have a clear advantage at histological and clinical levels versus those who do not achieve 
SVR (Muir et al., 2011).  Prior to the approval and use of DAAs, the treatment of HCV 
had not changed for 13 years, so the existing body of knowledge examining HCV-
infected African Americans with these new treatment options remains scarce.  In all 
phase III clinical trials of the first generation DAAs (TVR and BOC) plus peglyated 
interferon and ribavirin, African Americans only comprised 10.6% of combined 
enrollment (Burton et al., 2012).  When this African American cohort was analyzed, 
researchers found that SVR rates had vastly improved with the use of DAA therapy (TVR 
or BOC plus peglyated interferon and ribavirin) versus the previous non-DAA therapy 
(50-62% versus 19-21%, respectively; Burton et al, 2012).   
Clinical studies using second generation DAAs are eliminating the use of an 
interferon-based regimen, and therefore, removing the reduced treatment effect of the 
more prominent IL28B T/T genotype with the African American cohort.  Proof of 
concept studies have demonstrated that interferon-free, second generation DAA regimens 
(with or without ribavirin) are resulting in efficacious outcomes for this difficult to treat 
population (Highleyman, 2013; Osinusi, Bon, & Herrmann, 2013). 
Summary 
In the United States, African Americans are at particularly high risk of HCV 
infection.  Several researchers have demonstrated that HCV-infected African Americans 
suffer from poorer responses to treatment, lower rates of cure, higher incidences of liver 
cancer, higher death rates from liver cancer, and poorer survival rates with liver 
transplantation.  In addition, researchers have demonstrated that there are health 
disparities with HCV-infected African Americans as a result of injection drug use, lower 
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socioeconomic status, perceived or actual bias with health care, poorer access to care, and 
inappropriate treatment.  The NHANES datasets have been used extensively to study 
hepatitis C infection status in the U.S. population.  The addition of the Hepatitis C 
Follow-Up Questionnaire (HCQ) in 2001 along with years of testing participants for anti-
HCV antibody status have made the NHANES datasets very informative and useful.  For 
this study, I used the NHANES datasets over an 8-year period, 2005-2012, which 
included identification of those who are infected with HCV, race, and HCQ self-report 
responses, in order that I was able to examine the health care seeking behavior and 
provider responses in this cohort during both pre- (2005-2008) and post- (2009-2012) 
DAA periods.  In Chapter 3, I present the research design and approach used to address 
the research questions and hypotheses.  Additionally, I discuss the setting and sample of 
the study, and describe procedures for sampling, subject recruitment, and data collection.  
I also discuss the instrumentation validity and reliability, and operationalization of the 
variables.  The threats to validity and ethical considerations are also discussed in this 
chapter. 
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Chapter 3: Research Method 
Introduction 
In the United States, approximately 3.5 million persons carry chronic HCV 
infection, with African Americans carrying a disproportionately large burden of this 
disease (Centers for Disease Control and Prevention, 2012a).  African Americans (3%) 
carry a 2-fold higher prevalence when compared with Caucasians (1.5%) and Hispanics 
(1.3%; Kemmer & Neff, 2010).  A leading cause of death for African Americans ages 45-
64 is HCV-related chronic liver disease (Pearlman, 2006).  In addition, HCV-infected 
African Americans are afflicted with poorer survival rates from liver transplant and 
higher incidences of liver cancer and liver cancer-related mortality as compared to 
Caucasians (Layden et al., 2012).  When given treatment for HCV infection, African 
Americans have lower rates of response and viral clearance compared to Caucasians 
(Burton et al., 2012).  A high prevalence of injection drug use combined with lower 
socioeconomic status introduces limited access to health care, bias, stigmatization, and 
inferior quality of care (Davila & El-Serag, 2006; Sloane et al., 2006).  African 
Americans experience disparities in access to care that are reflected in the outcome and 
survival of HCV infection; along with the individual comorbidities that impact low 
treatment rates, African Americans are disproportionately affected by lack of adequate 
health insurance and high treatment costs (Melia et al., 2011).  As of 2008, there have 
been newer treatment options available that have substantially increased the rates of 
sustained virologic response (SVR) for all genotype 1 infected persons, including African 
Americans (Burton et al., 2012).  The most recent data on HCV infection in the U.S. 
population were collected by the 2011-2012 National Health and Nutrition Examination 
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Survey (NHANES).  In this quantitative study, I used secondary datasets from the 
NHANES and the Hepatitis C Follow-Up Questionnaire (HCQ) for the years 2005-2012 
to determine whether the seeking of health care by HCV-positive African Americans and 
health care provider responses to HCV-positive African Americans had improved since 
2008 following the introduction of new treatment options as compared to other HCV-
positive racial/ethnic groups. 
In this chapter, I describe the research methodology, including the study design 
and rationale.  I also describe the study population, sampling strategy, and procedures for 
sampling, recruitment, data collection, and quality assurance.  The independent and 
dependent variables and covariates are also defined and described.  Lastly, I discuss 
threats to validity, bias, methodological limitations, and ethical considerations.   
Research Design and Rationale 
 This study used a quantitative, nonexperimental research design with cross-
sectional survey data from four 2-year NHANES datasets and HCQs (2005-2012) to 
examine the health care seeking behavior and provider responses associated with HCV-
positive African Americans, as compared to other HCV-positive racial/ethnic groups, 
since 2008, when newer treatment options for HCV were made available in the United 
States.  The study compared the influence of race/ethnicity on health care seeking 
behavior and provider responses of HCV-positive HCQ respondents within two time 
periods, 2005-2008 and 2009-2012.  The dependent variables were health care seeking 
behavior and provider responses, and the independent variable was HCV-positive HCQ 
respondents.  The covariates included age, gender, race, education, poverty index, health 
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insurance status, and history of illegal injection drug use.  The research questions and null 
and alternate hypotheses leading this study were as follows: 
Research Question 1 
Has the seeking of health care, as defined by self-report HCQ responses, by HCV-
positive African Americans improved since 2008 following the introduction of new 
treatment options as compared to other HCV-positive racial/ethnic groups? 
Null hypothesis (H01): Seeking of health care, as defined by self-report HCQ 
responses, by HCV-positive African Americans has not improved since 2008 following 
the introduction of new treatment options as compared to other HCV-positive 
racial/ethnic groups. 
Alternative hypothesis (Ha1): Seeking of health care, as defined by self-report 
HCQ responses, by HCV-positive African Americans has improved since 2008 following 
the introduction of new treatment options as compared to other HCV-positive 
racial/ethnic groups. 
Research Question 2 
Has the response from health care providers, as defined by self-report HCQ 
responses, to HCV-positive African Americans improved since 2008 following the 
introduction of new treatment options as compared to other HCV-positive racial/ethnic 
groups? 
Null hypothesis (H02): The response from health care providers, as defined by 
self-report HCQ responses, to HCV-positive African Americans has not improved since 
2008 following the introduction of new treatment options as compared to other HCV-
positive racial/ethnic groups. 
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Alternative hypothesis (Ha2): The response from health care providers, as defined 
by self-report HCQ responses, to HCV-positive African Americans has improved since 
2008 following the introduction of new treatment options as compared to other HCV-
positive racial/ethnic groups. 
Quantitative methodology was selected for this study because this method can be 
used to analyze numerical data statistically to assess multiple variables, test hypotheses, 
and explain a particular phenomenon (Muijs, 2010).  The study hypotheses were tested 
using numerical variables, which were quantified by statistical analysis.  Correlational 
research is conducted in order to determine the extent of a relationship between two or 
more variables using statistical data and can be interpreted to recognize trends, but it does 
not go so far in its analysis as to establish cause and effect (Muijs, 2010).  Specific to this 
study was the relationship that existed between the identified variables of health care 
seeking behavior and provider responses with HCV-positive African Americans 
compared to other racial/ethnic groups and two 4-year time periods, 2005-2008 and 
2009-2012, which occurred before and after the introduction of newer treatment options, 
respectively.  By using quantitative statistical analysis, I was able to code data for 
analysis of relationships between the key variables (Field, 2013).  A qualitative research 
design would not have been appropriate for this study because it would have involved 
investigative methodologies such as ethnographic, naturalistic, anthropological, or 
participant observer approaches (Key, 1997).  Further, the qualitative method emphasizes 
the importance of looking at variables in a natural setting in which they are found (Key, 
1997).  
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 I conducted an inferential study to test the research hypotheses using secondary 
data from a cross-sectional survey study.  The use of cross-sectional survey data allows 
the researcher to look at the relationship between variables, and if the survey is repeated, 
the researcher can look at aggregate change over time in a population (King-Hele, 2005).  
Benefits of using successive cross-sectional survey data over time include the following: 
(a) a reasonable amount of comparability, (b) the data are representative at each specified 
time point (e.g., years), and (c) it is possible to examine impact on groups (King-Hele, 
2005).  Limitations of using successive cross-sectional survey data over time include: (a) 
reliance on the continuity of the data, (b) not being able to establish individual change, 
and (c) inability to determine a causal relationship (King-Hele, 2005).  Despite these 
limitations, the use of secondary data from a cross-sectional survey study was appropriate 
because this study investigated an association that had yet to be examined in the body of 
scientific knowledge. 
 Other quantitative methods such as ex post facto, quasi-experimental, and true 
experimental were not used because the purpose of those research methods did not fit the 
research objective.  Researchers conducting ex post facto studies investigate possible 
cause-and-effect relationships by observing an existing condition or state of affairs and 
searching back in time for plausible causal factors; those conducting true experimental 
studies deliberately control and manipulate the independent variable to observe the effect 
of that change on another dependent variable; and those conducting quasi-experimental 
studies make comparisons between groups that are not equal, or comparisons within a 
group over time (time-series; Creswell, 2009; Milstein & Wetterhall, 2013).  In this study, 
I evaluated whether health care seeking behavior and provider responses for HCV-
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positive African Americans, compared to other HCV-positive racial/ethnic groups, had 
changed since the introduction of newer treatment options, and as such, quantitative 
methodology using secondary data from a cross-sectional survey study was the 
appropriate means by which to evaluate these outcomes among the study population 
represented by NHANES 2005-2012. There were no time or resource constraints 
anticipated for this study. 
Methodology 
Setting and Sample 
This study used secondary data from four 2-year NHANES datasets (2005-2012).  
All of these datasets provided the independent and dependent variables and covariates in 
the public domain setting.  The target population for NHANES is the noninstitutionalized 
civilian population of the United States (Centers for Disease Control and Prevention, 
2013a).  The 2005-2012 NHANES datasets contained data for a total of 40,790 study 
participants who were interviewed; of these, 39,303 (96.3%) participants underwent the 
medical exam portion of the study (Centers for Disease Control and Prevention, 2014b).  
Of the study participants who underwent the medical exam portion of the study, there 
were 32,650 (83.0% of persons 6 years and older) who had serum samples drawn for the 
screening hepatitis C antibody test (Centers for Disease Control and Prevention, 2014b).  
The study population was defined as all NHANES participants 6 years of age and older 
who tested positive for the anti-HCV antibody and were contacted during the follow-up 
survey and interviewed.  For the NHANES 2005-2012 datasets, the total number of study 
participants who tested positive for the anti-HCV antibody was 394 (1.2% of all those 
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screened), of those, 132 (33.0%) completed the Hepatitis C Follow-Up Questionnaire 
(HCQ).  
 Sampling procedures. The NHANES used a stratified and multistage probability 
sampling design and collected information from persons using standardized household 
interviews, physical examinations, and testing of biologic samples; the data were 
published in 2-year cycles (Ditah et al., 2014).  The NHANES sampling procedure 
consisted of four stages (Centers for Disease Control and Prevention, 2013a).  Stage 1 
was the primary sampling units (PSUs); these were selected from strata defined by 
geography and proportions of minority populations, and were drawn mostly from single 
counties in the United States (Centers for Disease Control and Prevention, 2013a).  
Additional stages of sampling were performed to select for three secondary sampling 
units: (a) segments (city blocks) that were selected by probability proportional to a 
measure size, (b) households that were randomly drawn, and (c) individuals who were 
randomly drawn with designated age-sex-race/ethnicity screening subdomains (Centers 
for Disease Control and Prevention, 2013a).  In order to obtain correct national estimates 
from the NHANES data, each sampled person was assigned a numerical sample weight 
(Centers for Disease Control and Prevention, 2013a).  In addition, because the sample 
was defined by strata and by the primary and secondary sampling units, the sampling 
error was calculated on the counts of the groups, not the individuals; this also 
demonstrated a more efficient data collection process (Centers for Disease Control and 
Prevention, 2013a).   
Power analysis. The sample size was chosen in relation to population size as a 
result of a predefined subunit of the NHANES population: all HCV-positive participants 
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who completed the HCQ in the time period of 2005-2012.  The National Center for 
Health Statistics analytic guidelines state that data from the Hepatitis C Follow-Up 
Questionnaire (HCQ) should not be used with sample weights to make national estimates 
because of the small sample size and a response rate below 50% (Denniston et al., 2012).   
 The statistical power of a study represents the probability that the researcher will 
avoid making a Type I error of rejecting a null hypothesis that is true (Tomczak, 
Tomczak, Kleka, & Lew, 2014).  The higher or bigger the alpha level is (e.g., a = 0.05), 
the more likely the researcher will be to reject a true null hypothesis (a Type I error); the 
lower or smaller the alpha level is (e.g., a = .001), the more likely it is that the researcher 
will accept a false null hypothesis (a Type II error; Tomczak et al., 2014).   
I used G*Power v.3.1.9.2, an open domain statistical power analysis program, to 
calculate the sample size based upon an analysis of variance (ANOVA) statistical test 
(Buchner, Erdfelder, Faul, & Lang, 2013).  The calculation with G*Power included the 
following: (a) test family = F tests; (b) statistical test = ANOVA: fixed effects, special, 
main effects, and interactions; (c) type of power analysis = a priori: compute required 
sample size – given α, power, and effect size; (d) effect size f = .25 (as per Cohen’s 
conventions for medium effect size); (e) alpha level = 0.05; (f) power = 0.80; (g) 
numerator df = 1; and (h) number of groups = 2.  The G*Power analysis calculated the 
total sample size as 128 subjects.  
Procedures for Recruitment, Participation, and Data Collection 
The Division of Health and Examination Statistics releases NHANES public-use 
data files on a biannual basis, which, according to the data user agreement, must be used 
solely for the purpose of health statistical reporting and analysis as specified by the 
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Public Health Service Act [Section 308 (d)] (Centers for Disease Control and Prevention, 
2009b).  The households that were randomly selected and identified for inclusion in the 
NHANES sample were mailed an advance introductory letter informing them that an 
NHANES interviewer would be visiting their home (Centers for Disease Control and 
Prevention, 2010).  Upon arriving at the home, the NHANES interviewer provided an 
official identification badge; if the occupant had not seen the advance letter, a copy was 
given to the occupant for review (Centers for Disease Control and Prevention, 2010).  
The NHANES interviewer asked residents a few short questions (“Household Screener 
Questionnaire Module”) to determine if their household was eligible for the study; if one 
or more persons were selected to participate, consent forms were signed for both the 
household interview and medical examination components of the survey (Centers for 
Disease Control and Prevention, 2010).   
Household interview component. The household interview component (HIC) 
included demographic, socioeconomic, dietary, and health-related questions (Centers for 
Disease Control and Prevention, 2013a). The NHANES computer-assisted personal 
interview (CAPI) software program that was used to collect the interview data had built-
in data edit and consistency checks (Centers for Disease Control and Prevention, 2013a).  
The data edit checks alerted the interviewer when unusual or potentially erroneous data 
values were recorded; the consistency checks were used to alert the interviewer when 
information was recorded that was inconsistent with previous data entries or respondent 
characteristics such as the respondent’s age (Centers for Disease Control and Prevention, 
2013a).  Additional assistance in the interview process included preprogrammed 
questionnaire “skip” patterns to reduce respondent burden, as well as standardized 
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descriptions of the terminology and concepts that were used in the questionnaires 
(Centers for Disease and Prevention, 2013a). 
 Medical examination component. If a participant had agreed to complete the 
medical examination component (MEC), he or she was provided medical, dental, and 
physiological measurements, as well as laboratory tests administered by a MEC survey 
team (coordinator, manager, one physician, two dietary interviewers, three certified 
medical technologists, four health technicians, one phlebotomist, two interviewers, and 
one computer data manager; Centers for Disease Control and Prevention, 2010).  Some of 
the medical findings from the examination were given to the examinees before they 
exited the MEC; the other reportable survey findings were mailed to participants after the 
laboratory assays and special tests were completed (Centers for Disease Control and 
Prevention, 2010).   
 Screening for Hepatitis C. Participants 6 years of age or older who tested 
positive for anti-HCV antibody were sent a report of findings (ROF) letter that informed 
them (or parents of participants < 18 years of age) of the following: (a) HCV test result, 
(b) HCV transmission information, (c) effect on the liver, (d) effect on general health, 
and (e) encouragement to follow up with a healthcare provider (Denniston et al., 2012).  
Approximately 6 months following the ROF letter, a Hepatitis C Follow-Up 
Questionnaire (HCQ) was administered over the telephone (Denniston et al., 2012).  
Instrumentation and Materials 
 The NHANES is designed to assess the health and nutritional status of adults and 
children in the United States; findings are used to determine the prevalence of major 
diseases and risk factors for disease, as well as to expand health knowledge for the nation 
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to inform health programs and services (Centers for Disease Control and Prevention, 
2013a).  Based upon this scope, the NHANES survey represented the most applicable 
source of data for this study. 
 Age, gender, race, education, poverty index, health insurance status, and history 
of illegal injection drug use were collected via household interview component.  Anti-
HCV antibody level was determined via blood sample collected via venipuncture during 
the medical examination component of the survey.  Health care seeking behavior and 
provider response questions were collected using the 2005-2012 HCQs.  The 2005-2012 
Demographics modules collected the age, gender, race, education, and poverty index 
variables.  The 2005-2012 Questionnaire modules collected the variables of health 
insurance status, and history of illegal injection drug use.  
Study variables and covariates. A list of the independent variable, dependent 
study variables derived from the HCQ, and the covariates are provided in Table 1.   
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Table 1 
 
Independent and Dependent Variables and Covariates Used in This Study 
 
Variable type Variable name Variable source and 
label 
Value Level of 
measurement 
Independent Anti-HCV antibody 
 
Hepatitis C RNA 
MEC, LBDHCV 
 
MEC, LBXHCR 
1,2,5 
 
1,2 
Categorical  
 
Categorical 
 
HCQ—Health 
Care Seeking 
    
Dependent  Seen a doctor about test 
result? 
 
HCQ, HCQ070 1,2 Categorical 
Dependent  Have a doctor’s 
appointment? 
 
HCQ, HCQ080 1,2 Categorical 
Dependent  Why not treated? (patient 
decision) 
HCQ, HCQ140A-E  1,2 Categorical 
 
HCQ - Provider 
Response 
    
Dependent  Did doctor do additional 
tests? 
 
HCQ, HCQ090 1,2 Categorical 
Dependent What doctor told about 
test result? 
 
HCQ, HCQ100 1,2,3,4 Categorical 
Dependent Ever had a liver biopsy? 
 
HCQ, HCQ110 1,2 Categorical 
Dependent Doctor advised about 
medications? 
 
HCQ, HCQ121 1,2 Categorical 
Dependent Doctor advised you should 
be treated? 
 
HCQ, HCQ124 1,2 Categorical 
Dependent Doctor advised you should 
not be treated? 
 
HCQ, HCQ126A-E 
 
1,2 Categorical 
Dependent Treated with these 
medicines? 
 
HCQ, HCQ130 1,2 Categorical 
Covariate Gender Demographics module, 
RIAGENDR 
 
 
1,2 Categorical 
 
 
 
 
 
 
 
 
(table continues) 
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Variable type Variable name Variable source and 
label 
Value Level of 
measurement 
Covariate Age  Demographics module, 
RIDAGEYR 
 
0 to 85 Continuous 
Covariate Race/Ethnicity Demographics module, 
RIDRETH1 
 
1,2,3,4,5 Categorical 
Covariate Education (respondent 6-
19 years old) 
Demographics module, 
DMDEDUC3 
 
0 to 15  Categorical 
Covariate Education (respondent 
20+ years old) 
Demographics module, 
DMDEDUC2 
 
1,2,3,4,5 Categorical 
Covariate Poverty Index Demographics module, 
INDFMPIR 
 
0 to 5.0 Continuous 
Covariate Health insurance status Health insurance 
module, HIQ011 
 
1,2 Categorical 
Covariate History of  
illegal injection drug use 
Drug use module, 
DUQ370 
1,2 Categorical 
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Table 2 
 
Variable Source and Labels—Descriptions 
 
Variable label Description 
MEC Medical examination component 
LBDHCV Hepatitis C antibody (confirmed) 
LBXHCR Hepatitis C RNA (HCV-RNA) 
HCQ Hepatitis C Follow-Up Questionnaire 
RIAGENDR Gender 
RIDAGEYR Age at screening 
RIDRETH1 Race/Ethnicity 
DMDEDUC3 Education Level—Children/Youth 6-19 
DMDEDUC2 Education Level—Adults 20+ 
INDFMPIR Poverty income ratio (PIR) 
HIQ Health insurance 
DUQ Drug use 
 
Independent variable. The independent variable, anti-HCV antibody, is a value 
that was calculated on all examinees 6 years or older by a serum specimen with 
laboratory testing as follows: samples testing positive for anti-HCV by the screening test 
were tested in the confirmatory RIBA assay for antibody to hepatitis C virus; samples 
with a positive RIBA result were reported as confirmed positive for antibody to HCV 
(Centers for Disease Control and Prevention, 2012c).  Samples with a negative RIBA 
result were reported as such (Centers for Disease Control and Prevention, 2012c).  
Samples with an indeterminate RIBA result were tested for hepatitis C RNA (HCV-
RNA).  For inferential statistics, anti-HCV antibody was a categorical variable and 
reported as positive (1), negative (2), or indeterminate (3); HCV-RNA was a categorical 
variable and reported as positive (1), or negative (2).  Subjects who had positive anti-
HCV or positive HCV-RNA were included in the analysis.  Subjects who had negative or 
missing values were excluded from analysis. 
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 Dependent variables. The dependent variables were a specific series of questions 
from the HCQ that examined health care seeking behavior and provider responses.  Each 
variable had self-reported responses, and each variable was individually evaluated during 
the study analyses.  
Health care seeking behavior variables. Health care seeking behavior variables 
from the HCQ for this study included the following: 
• Seen a doctor about test result?  The test result was defined as either the 
participant’s first positive hepatitis C test, or the NHANES positive hepatitis 
C test.  This was a categorical variable and was reported as (1) yes, and (2) no. 
• Have an appointment to see a doctor about test result?  This was a categorical 
variable and was reported as (1) yes, and (2) no. 
• Why did you decide not to be treated?  This was a categorical variable that 
was reported as (1) yes, and (2) no for each of the 5 options provided by the 
interviewer: (a) side effects are unpleasant, (b) need to self-inject the medicine, 
(c) too expensive, (d) hope of better future treatments, and (e) some other 
reason given.  
Provider response variables. Provider response variables from the HCQ for this 
study included the following: 
• Did doctor do additional tests?  This was a categorical variable and was 
reported as (1) yes, and (2) no. 
• What doctor told you about test result?  This was a categorical variable and 
was reported as (1) hepatitis C and needs a regular medical follow-up, (2) 
tested positive for hepatitis C, but do not need to do anything or worry about it, 
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(3) really don’t have hepatitis C because a follow-up test showed that the 
positive test result was in error, and (4) Other. 
• Ever had a liver biopsy?  This was a categorical variable and was reported as 
(1) yes, and (2) no. 
• Doctor advised about medications used to treat hepatitis C?  This was a 
categorical variable and was reported as (1) yes, and (2) no. 
• Doctor advised you should be treated with medication such as interferon and 
ribavirin?  This was a categorical variable and was reported as (1) yes, and (2) 
no. 
• Doctor advised you should not be treated?  This was a categorical variable 
that was reported as (1) yes, and (2) no for each of the 5 options provided by 
the interviewer: (a) liver enzymes were normal, (b) did not have liver disease, 
(c) do not need to do anything, (d) can wait to be treated at a later time, and 
(e) no reason given. 
• Treated with these medicines?  This was a categorical variable and was 
reported as (1) yes, and (2) no. 
Covariates. Confounding variables for this study included gender, age, race, 
education, poverty index, health insurance status, and history of illegal injection drug use. 
• Gender.  Gender was a categorical variable and was reported as either male 
(1) or female (2).  All subjects had a reported gender.  There were no missing, 
refused, or unknown values for the sample population. 
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• Age.  Age was calculated based on participants’ date of birth.  If the actual 
date of birth was missing, then the reported age was used.  For NHANES 
2005-2006, age in years was reported as a continuous variable with ages 
between 1 and 84 years of age, and all adults who were 85 years and older 
were categorically assigned a value of ‘85’.  For NHANES 2007-2012, age in 
years was reported as a continuous variables with ages between 1 and 80 years 
of age, and all adults who were 80 years and older were categorically assigned 
a value of ‘80’.  All subjects had a reported age.  There were no missing, 
refused, or unknown values for the sample population.  For the inferential 
analysis, the age variable was recoded into age groups reported as (1) <30 
years, (2) 30-49 years (3) 50-69 years, and (4) 70+ years.  These age groups 
were chosen to capture the young persons (<30 years) and baby boomer (50-
69 years) cohorts at risk for HCV infection.  Seventy-five percent of all 
persons living with HCV infection and 75% of HCV-associated deaths are 
attributed to those who were born during the years of 1945 to 1965 (a.k.a., 
baby boomers; Centers for Disease Control and Prevention, 2015a).  In 2011, 
the Centers for Disease Control and Prevention Hepatitis C Surveillance found 
the largest increases in rate of acute hepatitis C among persons aged 0-29 
years when compared to all age groups; in addition, researchers found a trend 
of increasing HCV infections among adolescents and young adults in the 
United States (Centers for Disease Control and Prevention, 2014c). 
• Race/Ethnicity.  This was a categorical variable and was reported as Mexican 
American (1), Other Hispanic (2), Non-Hispanic White (3), Non-Hispanic 
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Black (4), and Other Race – Including Multi-Racial (5).  If respondents self-
identified as “Mexican American” they were coded as such; if respondents 
self-identified as “Hispanic” they were coded as “Other Hispanic” (Centers 
for Disease Control and Prevention, 2012c).  All other respondents were 
categorized based on their self-reported races as coded above.  There were no 
missing, refused, or unknown values for the sample population.  For the 
inferential analysis, the race variable was recoded into three categorical 
groups reported as (1) Caucasian, (2) African American, and (3) 
Hispanic/other. 
• Education.  There were two scales used for this categorical variable: ages 6-19 
years and 20+ years.  For those ages 6-19 years, the codes were the highest 
grade or level of education and reported as (0) never attended/kindergarten 
only, (1-12) single grades 1 thru 12, (13) high school graduate, (14) GED or 
equivalent, and (15) more than high school.  For those ages 20 and over, the 
codes were reported as (1) less than 9th grade, (2) 9-11th grade (includes 12th 
grade with no diploma), (3) high school graduate/GED or equivalent, (4) some 
college or AA degree, and (5) college graduate or above.  There were no 
missing, refused, or unknown values for the sample population.  For the 
inferential analysis, the education variable for ages 6-19 years was recoded 
into the same education groups as the ages 20 years and older scale.  This 
allowed the merging of all persons ages 6 and older into the following 
education groups reported as (1) less than high school (includes 12th grade 
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with no diploma), (2) high school graduate/GED or equivalent, (3) more than 
high school, and (4) Don’t know. 
• Poverty Index.  This number was calculated by dividing family income by the 
poverty guidelines, specific to family size, as well as the appropriate year and 
state.  This continuous variable was reported as a range value from 0 to 5.00 
with values at or above 5.00 coded as 5.00 or more.  For the inferential 
analysis, the poverty index variable was recoded into three categorical groups 
reported as (1) < 1.0 (below poverty level), (2) 1.0-1.9 (near poverty level), 
and (3) 2.0 or greater (above poverty level).  There were 15 missing values for 
the sample population. 
• Health Insurance Status.  This was a categorical variable and was reported as 
(1) yes or (2) no.  There were no missing, refused, or unknown values for the 
sample population. 
• History of Illegal Injection Drug Use.  This was a categorical variable and was 
reported as (1) yes or (2) no.  The age groups for each of the NHANES 
datasets that was released for this variable included: 2005-2006 ages 20-59, 
2007-2008 ages 20-69, 2009-2010 ages 18 and older, 2011-2012 ages 18-69. 
There were 19 missing values for the sample population. 
Data Analysis Plan 
 NHANES 2005-2012 data were released to the public in SAS transport files 
(Centers for Disease Control and Prevention, 2013c).  All relevant data files required for 
the study were opened by the software application Statistical Package for the Social 
Sciences (SPSS) version 21.0, and then converted and used in SAV format for all data 
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analyses that was performed.  SPSS was suitable for this study because it was able to do 
merging, coding, and recoding of data, in addition to generating tabulated reports, charts, 
plots of distributions and trends, descriptive statistics, and complex data manipulation 
and analysis (Field, 2013).  
 The 2005-2012 NHANES data sets that were downloaded from the Centers for 
Disease Control and Prevention website included: (a) demographics, (b) health insurance, 
(c) drug use, (d) laboratory – hepatitis C, and (e) HCQ.  Frequency counts were 
performed and matched against reported frequencies for each variable in the Data 
Documentation, Code Book and Frequencies reports for the years 2005-2012 issued by 
the Centers for Disease Control and Prevention (2013a).  All survey data had built in edit 
and consistency checks and quality control measures after collection including staff 
review and external verification with respondents (Centers for Disease Control and 
Prevention, 2013b).  The NHANES Medical Examination Component laboratory is a 
Clinical Laboratory Improvement Act (CLIA)-certified lab and used both internal and 
external surveillance measures to monitor quality assurance and quality control (Centers 
for Disease Control and Prevention, 2014d).  Missing values counts from downloaded 
data variables were verified against the CDC reported missing value counts in the public 
files.  All missing values were deleted and excluded for analysis thus eliminating any 
potential for missing value bias.  I used both descriptive and inferential statistics in this 
study.  Descriptive statistics simply describes what is or what the data shows with simple 
summaries about the sample and the measures; inferential statistics allows the researcher 
to try and reach conclusions that extend beyond the immediate data alone (Field, 2013).   
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 Descriptive statistics. The characteristics of participants for the NHANES data 
set were summarized into two time periods, 2005-2008 and 2009-2012, using a frequency 
table that reports the number and percentage of occurrence.  This included: (a) total 
number of participants who completed the HIC and MEC, (b) total number of participants 
who had a serum sample tested for anti-HCV antibody, (c) total number of participants 
who were anti-HCV positive, and (d) total number of participants who completed the 
HCQ.  The characteristics of the participants who completed the HCQ were reported in 
two time periods, 2005-2008 and 2009-2012, using a frequency table and included the 
number and percentage for the covariates of age, gender, race, education, poverty index, 
health insurance status, and history of illegal injection drug use.  The characteristics of 
the participants who completed the HCQ were reported by three racial/ethnic groups 
(Caucasian, African American, Hispanic/Other) in two time periods, 2005-2008 and 
2009-2012, and used a frequency table that included the number and percentage for the 
covariates of age, gender, education, poverty index, health insurance status, and history 
of illegal injection drug use. 
 Inferential statistics. Inferential statistical methods were used to answer the 
research questions.  The chi-square test for independence was used to examine if there 
was a relationship between two or more categorical variables (Laerd Statistics, 2013).  In 
order to conduct this test, two assumptions needed to be met: (a) the two variables should 
be measured at an ordinal or nominal level, and (b) the two variables should consist of 
two or more categorical, independent groups (Laerd Statistics, 2013).  This method was 
appropriate to test the hypotheses of the study as it did not require normal distribution or 
variance assumptions about the populations from which the samples were drawn and was 
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designed for ordinal or nominal data (Laerd Statistics, 2013).  For each of the 10 
dependent variables (HCQ responses), a chi-square test for independence was conducted 
with three racial/ethnic groups (Caucasian, African American, Hispanic/Other) to 
compare the differences with their health care seeking behavior and provider responses 
before the introduction of new treatment options (time period 2005-2008) and after the 
introduction of new treatment options (time period 2009-2012).  If the sample size was 
smaller than 5, a Fisher’s exact test was conducted.  In order to account for confounders, 
I used multiple logistic regression and explored the associations between the HCQ 
responses of each racial/ethnic group in two time periods as described above.  The 
multiple logistic regression model included the covariates of age, gender, education, 
poverty index, health insurance status, and history of illegal injection drug use.  Specific 
statistical methods used to test the hypotheses are described below. 
 Research Question 1. Has the seeking of health care, as defined by self-report 
HCQ responses, by HCV-positive African Americans improved since 2008 following the 
introduction of new treatment options as compared to other HCV-positive racial/ethnic 
groups? 
Null hypothesis (H01): Seeking of health care, as defined by self-report HCQ 
responses, by HCV-positive African Americans has not improved since 2008 following 
the introduction of new treatment options as compared to other HCV-positive 
racial/ethnic groups. 
Alternative hypothesis (Ha1): Seeking of health care, as defined by self-report 
HCQ responses, by HCV-positive African Americans has improved since 2008 following 
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the introduction of new treatment options as compared to other HCV-positive 
racial/ethnic groups. 
To test Research Question 1, a chi-square test for independence was conducted 
with three categorical independent HCV-positive racial/ethnic groups who were HCQ 
respondents (Caucasian, African American, Hispanic/Other).  Each racial/ethnic group’s 
HCQ answers were compared for two time periods (2005-2008 and 2009-2012).  Health 
care seeking behavior was defined as the following three HCQ answers: (a) I saw a 
doctor about the hepatitis C test result, (b) I have an appointment to see a doctor about the 
hepatitis C test result, and (c) I decided not to get treated because (5 choices): side effects 
are unpleasant, need to self-inject medicine, too expensive, hope of future better 
treatments and, some other reason given.  An improvement is defined as an increase in 
the number of individuals who saw a doctor or have an appointment to see a doctor, and a 
decrease in the number of individuals who decided not to get treated.  Any probability 
value of significance (p-value) which is less than or equal to the level of significance 
(0.05) was considered statistically significant.  Given that multiple factors can influence 
health care seeking behavior, a multivariable logistic regression analysis was conducted 
in order to determine the independent relation between the three HCQ answers of HCV-
positive participants in two time periods (2005-2008 and 2009-2012) after controlling for 
the covariates of age, gender, race/ethnicity, education, poverty index, health insurance 
status, and history of illegal injection drug use. 
Research Question 2. Has the response from health care providers, as defined by 
self-report HCQ responses, to HCV-positive African Americans improved since 2008 
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following the introduction of new treatment options as compared to other HCV-positive 
racial/ethnic groups? 
Null hypothesis (H02): The response from health care providers, as defined by 
self-report HCQ responses, to HCV-positive African Americans has not improved since 
2008 following the introduction of new treatment options as compared to other HCV-
positive racial/ethnic groups. 
Alternative hypothesis (Ha2): The response from health care providers, as defined 
by self-report HCQ responses, to HCV-positive African Americans has improved since 
2008 following the introduction of new treatment options as compared to other HCV-
positive racial/ethnic groups. 
To test Research Question 2, a chi-square test for independence was conducted 
with three categorical independent HCV-positive racial/ethnic groups who were HCQ 
respondents (Caucasian, African American, Hispanic/Other).  Each racial/ethnic group’s 
HCQ answers were compared for two time periods (2005-2008 and 2009-2012).  The 
response from health care providers was defined as the following seven HCQ answers: 
(a) the doctor did other blood tests to check the liver, (b) the doctor told me I need regular 
medical follow-up, (c) the doctor told me I do not need to do anything or worry about my 
hepatitis C, (d) I had a liver biopsy, (e) the doctor told me there are medicines that can be 
used to treat hepatitis C, (f) I was treated with the medication, (g) the doctor told me I 
should not be treated because (5 choices): liver enzymes are normal, do not have liver 
disease, don’t need to do anything, wait to be treated at a later time and, no reason 
specified.  For response from health care providers, an improvement was defined as an 
increase in the number of individuals who: (a) had additional tests done, (b) need regular 
63 
 
medical follow-up, (c) had a liver biopsy, (d) informed there are medicines that can be 
used to treat hepatitis C, and (e) who were given medication for their HCV infection.  
Any probability value of significance (p-value) which is less than or equal to the level of 
significance (0.05) was considered statistically significant.  Given that multiple factors 
can influence responses from a health care provider, a multivariable logistic regression 
analysis was conducted in order to determine the independent relation between the seven 
HCQ answers of HCV-positive participants in two time periods (2005-2008 and 2009-
2012) after controlling for the covariates of age, gender, race/ethnicity, education, 
poverty index, health insurance status, and history of illegal injection drug use. 
Threats to Internal and External Validity 
There are threats that exist with both internal and external validity and can occur 
at any time during the research process (Creswell, 2009). The NHANES has been utilized 
as a nationwide surveillance system for over 40 years; in addition, the analyses of 
responses from the U.S. noninstitutionalized adult population indicated that the 
NHANES measures had good construct validity (Centers for Disease Control and 
Prevention, 2013a).  In using secondary data analysis, assessing the validity of the 
measures includes examining the questions that were asked for face validity; there is a 
threat if the questions are found to be meaningless, problematic or open to a range of 
interpretation (Creswell, 2009).  Internal validity is focused on the study design and the 
degree of control applied over potential extraneous variables that can threaten the internal 
validity (Slack & Draugalis, 2001).  This control can lessen the potential for alternative 
explanations for treatment effects while consequently providing more confidence that the 
effects are due to the independent variable (Slack & Draugalis, 2001).  When a researcher 
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draws incorrect inferences from the study data to other past or future settings it introduces 
threats to external validity (Creswell, 2009). 
With regard to the validity of the NHANES survey instrument, a thorough 
examination of the instrument will include information on all three types of validity: 
content, construct, and empirical (Frankfort-Nachmias & Nachmias, 2008).  To ensure 
content validity of this instrument, face validity can be utilized to compare the questions 
to other questionnaires on the same subject (e.g. hepatitis c status, health status; 
Frankfort-Nachmias & Nachmias, 2008).  For the launch of the continuous survey, and 
biannually after the survey began, new content proposals were solicited and ascertained if 
they were safe, feasible, and of sufficient public health significance, as well as 
appropriateness and feasibility, to include in NHANES (Centers for Disease Control and 
Prevention, 2013d).  This demonstrated an establishment of construct validity by 
determining whether the instrument is logically and empirically tied to the concepts and 
theoretical assumptions that are being employed in the research studies (Frankfort-
Nachmias & Nachmias, 2008).  If the proposal was accepted, the protocol was fully 
developed and prepared for field-testing prior to use in NHANES (Centers for Disease 
Control and Prevention, 2013d).  This addressed the empirical validity of the instrument 
by examining the relationship between the measuring instrument and the measured 
outcomes, as they relate to the real world and the variables being measured (Frankfort-
Nachmias & Nachmias, 2008). With regard to laboratory methods, they were tested and 
deemed reliable and valid prior to their inclusion in NHANES (Centers for Disease 
Control and Prevention, 2013d).   
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Bias and Methodological Limitations 
Bias is the result of systematic errors in the research study that result in an 
incorrect estimate of the association between exposures and outcomes.  The types of 
biases addressed here include sampling bias, selection bias, nonresponse bias, and recall 
bias.  Methodological limitations are also addressed which may impact or limit further 
studies.  
Bias in sampling is a systematic error in sampling procedures that leads to a 
distortion in the results of the study and eliminates the representativeness of the sample 
(Frankfort-Nachmias & Nachmias, 2008).  The NHANES sampling procedure consisted 
of four stages (Centers for Disease Control and Prevention, 2013a). Stage 1 was the 
primary sampling units (PSUs); these were selected from strata defined by geography and 
proportions of minority populations, and were mostly single counties in the United States 
(Centers for Disease Control and Prevention, 2013a). Additional stages of sampling were 
performed to select for three secondary sampling units: (a) segments (city blocks) that 
were selected by probability proportional to a measure size, (b) households that were 
randomly drawn, and (c) individuals that were randomly drawn with designated age-sex- 
race/ethnicity screening sub-domains (Centers for Disease Control and Prevention, 
2013a). In order to obtain correct national estimates from the NHANES data, each 
sampled person was assigned a numerical sample weight (Centers for Disease Control 
and Prevention, 2013a). In addition, because the sample is defined by strata and by the 
primary and secondary sampling units, the sampling error was calculated on the counts of 
the groups, not the individuals; this also demonstrated a more efficient data collection 
process (Centers for Disease Control and Prevention, 2013a). Overall, the NHANES 
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dataset assisted with controlling for sampling bias because it did not favor one group over 
another, but used a cross-section of all persons who reply to be surveyed in the United 
States (Frankfort-Nachmias & Nachmias, 2008).  In this same vein, selection bias was 
also reduced using this complex sampling method of patient selection. 
Nonresponse bias occurs when some respondents included in the sample do not 
respond (Creswell, 2009).  Because NHANES used a complex sample design, sample 
weights were used to account for stratification, clustering, and the unequal probability of 
subject selection into the survey (Perlin, 2003).  Each NHANES oversampled certain 
population subgroups, and this was taken into account through appropriate weighting.  
The issue of using weights was critical to the correct analysis of NHANES data; 
inappropriate use of weights may have resulted in a flawed analysis and questionable 
study results (Perlin, 2003).  Sample weights were also used to adjust for possible bias 
resulting from subject nonresponse (Perlin, 2003).  Nonresponse is a key issue with any 
survey, and nonresponse bias needs to be assessed, reported, and include any information 
on reasons for missing data (Perlin, 2003).   
In addressing methodological limitations, when analyzing the NHANES data, 
sample weights were used to produce correct population estimates because each sample 
weight does not have equal probability of selection into the survey (Perlin, 2003).  
Although the current NHANES was conducted using annual samples that are nationally 
representative, the sample size in any one year was relatively small, resulting in large 
variability for estimates, especially with detailed analyses such as the study’s primary 
cohort of only HCV-positive participants (Perlin, 2003).  Another analytic limitation is 
that the NHANES sample was selected from a relatively small number of sampling units 
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(PSUs) or counties which can introduce a higher level of uncertainty in the annual 
estimates (Perlin, 2003).  The computation of 2-year datasets was preferred to decrease 
variability in annual estimates.  
Ethical Procedures and Considerations 
Institutional Review Board (IRB) approval is required for all research involving 
human subjects.  Human subjects are defined as one or more living individuals about 
whom an investigator (whether professional or student) conducting research obtains (a) 
data through intervention or interaction with the individual or, (b) identifiable private 
information (U.S. Department of Health and Human Services, 2014).  This study used 
archived, deidentified secondary data that had been released by the Centers for Disease 
Control and Prevention (2012b) to the public domain and may be reproduced without 
permission; therefore, I did not need to obtain informed consent.  This study received 
Walden University Institutional Review Board approval prior to any data analysis (IRB 
Approval Number: 08-06-15-0171822).  In doing so, I was protecting the University, the 
study participants, and myself by ensuring that my dissertation research was in 
compliance with the University’s ethical standards as well as U.S. federal regulations 
(Walden University, 2014).  Regarding the IRB’s process for NHANES, the National 
Center for Health Statistics had a Research Ethics Review Board that approved each 
NHANES survey; the protocol number and approval information can be obtained and 
referenced from the Centers for Disease Control and Prevention (2012b) website: 
http://www.cdc.gov/nchs/nhanes/irba98.htm 
The main ethical consideration with this research study was the protection of the 
survey participants’ identity.  In order to protect subject confidentiality, the NHANES did 
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not include certain information (e.g., subject address or location, date of birth) with the 
publically available data; in addition, many data elements were never be made available 
to the public (Perlin, 2003).  Laboratory samples, medical examinations, and survey 
responses were all deidentified and identifier code numbers were used in place of names 
or other identifying information (Centers for Disease Control and Prevention, 2012b).  
With HCV testing, the only demographic information attached to the HCV serum 
samples was age in 20-year groups, sex, race or ethnic group, and sampling location 
(Perlin, 2003).   
Prior to the Centers for Disease Control and Prevention (2012b) collecting the 
health information for the NHANES, they obtained informed consent from all survey 
participants assuring them that data collected was only to be used for stated purposes and 
would not be disclosed or released to others without consent of the individual or the 
establishment “in accordance with section 308(d) of the Public Health Service Act”.  An 
informed consent was provided to disclose that blood samples were to be tested, and 
maximum safeguards would be utilized to protect each sample person’s confidentiality 
(Perlin, 2003).  The NHANES consent also informed participants that the Centers for 
Disease Control and Prevention (2011) allowed other collaborators and researchers to use 
survey data, but their privacy was protected by the assignment of code numbers in place 
of names, and abstaining from revealing any other facts that could directly identify the 
person.  Storage of all data will be maintained in two locations, a laptop computer and an 
external hard drive, for no less than five years upon completion of the dissertation, and 
with sole accessibility of myself only.  This study was performed to fulfill the 
requirements for the Doctorate of Philosophy in Public Health and Epidemiology at 
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Walden University.  I have no financial interest in Walden University and claim no 
financial or other conflicts of interest with any other party. 
Summary 
In Chapter 3, I presented the detailed methodology of this research study, which 
included the research design and approach used to address the research questions and 
hypotheses.  Additionally, I discussed the setting and sample of the study and described 
procedures for sampling, subject recruitment, and data collection.  I also discussed the 
instrumentation validity and reliability and operationalization of the variables.  Threats to 
validity and ethical considerations were also discussed in this chapter.  In Chapter 4, I 
discuss the results of the statistical analyses, as well as the results of each of the research 
questions.   
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Chapter 4: Results 
Introduction 
The purpose of this study was to examine health care seeking behavior and 
provider responses for HCV-positive African Americans in the noninstitutionalized U.S. 
population.  The research questions and associated null hypotheses for this study were: 
Research Question 1: Has the seeking of health care, as defined by self-report 
HCQ responses, by HCV-positive African Americans improved since 2008 following the 
introduction of new treatment options as compared to other HCV-positive racial/ethnic 
groups? 
Null hypothesis (H01): Seeking of health care, as defined by self-report HCQ 
responses, by HCV-positive African Americans has not improved since 2008 following 
the introduction of new treatment options as compared to other HCV-positive 
racial/ethnic groups. 
Alternative hypothesis (Ha1): Seeking of health care, as defined by self-report 
HCQ responses, by HCV-positive African Americans has improved since 2008 following 
the introduction of new treatment options as compared to other HCV-positive 
racial/ethnic groups. 
Research Question 2: Has the response from health care providers, as defined by 
self-report HCQ responses, to HCV-positive African Americans improved since 2008 
following the introduction of new treatment options as compared to other HCV-positive 
racial/ethnic groups? 
Null hypothesis (H02): The response from health care providers, as defined by 
self-report HCQ responses, to HCV-positive African Americans has not improved since 
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2008 following the introduction of new treatment options as compared to other HCV-
positive racial/ethnic groups. 
Alternative hypothesis (Ha2): The response from health care providers, as defined 
by self-report HCQ responses, to HCV-positive African Americans has improved since 
2008 following the introduction of new treatment options as compared to other HCV-
positive racial/ethnic groups. 
These hypotheses were tested using secondary data from the National Health and 
Examination Survey (NHANES) 2005-2012, which was a stratified, multistage 
probability sample of the civilian, noninstitutionalized U.S. population.  The study 
analyzed data from participants who tested positive for past or current HCV infection and 
were interviewed as part of the Hepatitis C Follow-Up Questionnaire (HCQ) during the 
NHANES conducted from 2005 through 2012.  The associations between dichotomous 
HCQ responses from three racial/ethnic groups (Caucasian, African American, 
Hispanic/Other) were compared to evaluate the differences in health care seeking 
behavior and provider responses before the introduction of new treatment options (time 
period 2005-2008) and after the introduction of new treatment options (time period 2009-
2012) using chi-square test of independence.  If the sample size was smaller than 5, a 
Fisher’s exact test was conducted.  The associations between the HCQ responses of each 
of the three racial/ethnic groups from two time periods, 2005-2008 and 2009-2012, with 
the covariates of age, gender, education, poverty index, health insurance status, and 
history of illegal injection drug use, were analyzed using binomial logistic regression.   
In this chapter, I present the descriptive statistics of the dichotomized dependent 
and independent variables as well as the study covariates.  I also present the results for 
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the inferential statistics analysis and hypothesis testing for the two research questions, as 
well as summarize the significant findings as they relate to the research questions. 
Data Collection 
The secondary source of the data, the NHANES survey, used a stratified and 
multistage probability sampling design and collected information from persons using 
standardized household interviews, physical examinations, and testing of biologic 
samples; the data were published in 2-year cycles (Centers for Disease Control and 
Prevention, 2013a).  The NHANES sampling procedure consisted of four stages (Centers 
for Disease Control and Prevention, 2013a).  Stage 1 was the primary sampling units 
(PSUs); these were selected from strata defined by geography and proportions of 
minority populations and were mostly single counties in the United States (Centers for 
Disease Control and Prevention, 2013a).  Additional stages of sampling were performed 
to select for three secondary sampling units: (a) segments (city blocks) that were selected 
by probability proportional to a measure size, (b) households that were randomly drawn, 
and (c) individuals who were randomly drawn with designated age-sex-race/ethnicity 
screening subdomains (Centers for Disease Control and Prevention, 2013a).  In order to 
obtain correct national estimates from the NHANES data, each sampled person was 
assigned a numerical sample weight (Centers for Disease Control and Prevention, 2013a).  
In addition, because the sample was defined by strata and by the primary and secondary 
sampling units, the sampling error was calculated on the counts of the groups, not the 
individuals; this also demonstrated a more efficient data collection process (Centers for 
Disease Control and Prevention, 2013a).  Data for the 2005 through 2012 surveys were 
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collected between January 2005 and December 2012 (Centers for Disease Control and 
Prevention, 2013a).   
For the NHANES 2005 through 2012, a total of 40,790 participants completed the 
household interview component (HIC); of these, a total of 39,303 (96.3%) participants 
underwent the medical examination component (MEC; Centers for Disease Control and 
Prevention, 2014b).  Participants 6 years of age or older who had a positive test result for 
anti-HCV or, beginning in 2007, had an indeterminate test result for anti-HCV and a 
positive HCV-RNA, were sent a report of findings (ROF) letter informing them, or the 
parents of individuals < 18 years of age, of their HCV test result and encouraging them to 
follow up with a health care provider. Approximately 4 to 5 months after the ROF was 
mailed, a Hepatitis C Follow-Up Questionnaire (HCQ) was administered by telephone.  
Persons > 18 years of age were interviewed directly; an adult proxy provided information 
for individuals < 18 years of age and for individuals unable to answer themselves.  The 
HCQ was mentioned in the informed consent and also in the ROF letter.  The sample for 
analysis was all individuals who completed the HCQ 2005 through 2012.  
Results 
Univariate Analysis 
 NCHS analytic guidelines state that data from the Hepatitis C Follow-Up 
Questionnaire (HCQ) should not be used with sample weights to make national estimates 
because of small sample size and a response rate below 50% (Centers for Disease Control 
and Prevention, 2012c).  Therefore, analyses were conducted in SPSS 21.0 using chi-
square and, where appropriate (i.e., small cell sizes), Fisher’s exact tests.  Percentages 
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reported are percentages of respondents, not population estimates.  Results were 
considered statistically significant at the 0.05 level. 
Data from four 2-year cycles (2005-2012) of the Hepatitis C Follow-Up 
Questionnaire were combined with the NHANES demographic information, health 
insurance, and injection drug use data.  As shown in Table 3, a total of 32,630 (83.0%) 
participants had serum samples drawn for the screening hepatitis C antibody test; the total 
number of individuals who had a positive HCV result was 394 (1.2% of all those 
screened), of which 132 (33.5%) completed the Hepatitis C Follow-Up Questionnaire 
(HCQ).   
Table 3 
 
Characteristics of Participants, NHANES, Time Periods 2005-2008 and 2009-2012 
 
 
 
NHANES  
2005-2012 
NHANES  
2005-2008 
NHANES  
2009-2012 
Number of participants 40,790 20,497 20,293 
       N          %       N          %      N          %            
Completed HIC and MEC*   39,303    96.3  19,712     96.2 19,591     96.5 
Tested for anti-HCV   32,630    83.0 16,218      82.3 16,412     83.8 
Positive for anti-HCV**        394      1.2      194        1.2     200        1.2 
Completed HCQ***        132    33.5        66      34.0       66      33.0 
* = Household interview component and medical examination component. 
** = All positive anti-HCV results and indeterminate anti-HCV results that tested  
positive for HCV-RNA. 
*** = Hepatitis C Follow-Up Questionnaire. 
 
All results pertain to the “study sample” of 132 individuals who tested positive for 
current or past infection and responded to the HCQ, and are compared in two 4-year time 
periods, 2005-2008 and 2009-2012; therefore, these results are not generalizable.  Table 4 
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reports the frequencies and percentages for the categorical variables of characteristics for 
the study sample (n = 132), the 2005-2008 sample (n = 66), and the 2009-2012 sample (n 
= 66).  Using chi-square test of difference between the two time periods, participants in 
the 2005-2008 time period were more likely to be younger than age 50 (p < 0.05) and 
Caucasian (p  < 0.05) as compared to participants in the 2009-2012 time period (Table 4).  
The results demonstrated no statistically significant difference of participants between the 
two time periods when comparing the characteristics of gender, education, poverty index 
level, health insurance status, and history of illegal injection drug use. 
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Table 4 
 
Characteristics of Participants, NHANES Hepatitis C Follow-Up Questionnaire,  
Time Periods 2005-2008 and 2009-2012 
 
 
 
Study  
sample 
2005–2008 
sample 
2009–2012 
sample 
 
Sample size 132 66 66  
    N         %    N          %    N          % P value* 
Age group (years)     
< 30      3       2.3       3       4.5      0  
30-49    46     34.8     30     45.5    16      24.2 <0.05 
50-69    77     58.3     33     50.0    44      66.7  
70 +      6       4.6       0            6        9.1  
Gender     
Male    83     62.9     39     59.1    44      66.7  
Female    49     37.1     27     40.9    22      33.3  
Race/ethnicity     
Caucasian    51     38.6     33     50.0    18      27.3 < 0.05 
African American    47     35.6     20     30.3    27      40.9  
Hispanic/other    34     25.8     13     19.7    21      31.8  
Education     
Less than high schoola    45     34.1     18     27.2    27      40.9  
HS graduate/GED    40     30.3     28     42.5    12      18.2  
More than high school    46     35.1     20     31.3    26      39.3  
Don’t know      1       1.0        1        1.5  
Income     
Below poverty level    33     28.2     14     23.3    19      33.3  
        Near poverty level    44     37.6     26     43.3    18      31.6  
Above poverty level    40     34.2     20     33.3    20      35.1  
Missing 
Health insurance 
       6            9  
Yes    95     71.2     50     75.8    45      68.2  
No    37     28.0     16     24.2    21      31.8  
History of illegal 
injection drug use 
    
Yes    57     50.4     29     49.2    28      51.9    
No 
Missing 
   56     49.6     30     50.8 
      7 
   26      48.1 
   12 
 
 
* = P value for chi-square test of difference between time periods 2005-2008 and 2009-
2012. (Fisher’s exact test used for small cell sizes). 
a = includes 12th grade with no diploma. 
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The characteristics of the study sample were also analyzed by three racial/ethnic 
groups (Caucasian, African American, and Hispanic/Other) between the two time periods, 
2005-2008 and 2009-2012, and reported as frequencies and percentages as shown in 
Table 5.  Using chi-square test of difference to compare each racial/ethnic group (e.g. 
Caucasian v. Caucasian) between the two time periods, the Hispanic/Other group in the 
2005-2008 time period were more likely to be younger than 50 years of age (p < 0.05) as 
compared to the Hispanic/Other group in the 2009-2012 time period.  The results 
demonstrated no additional statistically significant difference with each racial/ethnic 
group between the two time periods when comparing the characteristics of gender, 
education, poverty index level, health insurance status, and history of illegal injection 
drug use.  
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Table 5 
 
Characteristics of Participants by Race/Ethnicity, NHANES Hepatitis C Follow-Up 
Questionnaire, Time Periods 2005-2008 and 2009-2012 
 
 
 
                2005–2008 
                    sample 
                   (N = 66)                                                                                                                    
                 2009–2012 
                     sample 
                    (N = 66) 
 
Race/Ethnicity 
Caucasian    African     Hispanic/ 
                   American       Other 
Caucasian    African     Hispanic/ 
           American      Other 
    N      %      N      %       N      %     N      %       N      %     N       % 
Age group (years)   
< 30   2      66.7      0               1    33.3*   0       0.0       0      0.0    0      0.0 
30-49 19      63.3      5    16.7    6    20.0*   6     37.5       3    18.8    7    43.8 
50-69 12      36.4    15    45.5    6    18.2 12     27.3     18    40.9  14    31.8 
70 +   0        0.0      0      0.0    0      0.0   0       0.0       6  100.0    0      0.0 
 
Gender 
  
Male 20      51.3    12    30.8    7    17.9 12     27.3     18    40.9  14    31.8 
Female 13      48.1      8    29.6    6    22.2   6     27.3       9    40.9    7    31.8 
 
Education 
  
Less than  
high school** 
  7      38.8      8    44.4    3    16.7   5     18.5       8    29.6  14    51.9 
H.S. graduate/GED 16      57.1      7    25.0    5    17.9   4     33.3       6    50.0    2    16.7 
More than H.S. 10      50.0      5    25.0    5    25.0   9     34.6     12    46.2    5    19.2 
Don’t know                         1      3.7 
 
Poverty indexa 
  
< 1.0 (below poverty)   8      57.1      5    35.7    1     7.1   4     21.1       8    42.1    7    36.8 
1.0-1.9 (near poverty) 15      57.7      4    15.4    7   26.9   8     44.4       4    22.2    6    33.3 
2.0+ (above poverty)   9      45.0      9    45.0    2   10.0   3     15.0     12    60.0    5    25.0 
 
Have health insurance  
  
Yes 20      40.0    17    34.0  13   26.0 11     24.4     21    46.7  13    28.9 
No 13      81.3      3    18.8    0     0.0   7     33.3       6    28.6    8    38.1 
 
History of illegal injection drug 
useb 
  
Yes 16      55.2      7    24.1    6   20.7   9     32.1       9    32.1  10    35.7 
No 15      50.0    11    36.7    4   13.3   7     26.9     11    42.3    8    30.8 
* = P value < 0.05 for chi-square test of difference for comparison of each racial/ethnic group between time 
periods 2005-2008 and 2009-2012 (Fisher’s exact test used for small cell sizes). 
** = Includes 12th grade with no diploma 
a = 2005-2008: n = 60 (6 missing data); 2009-2012: n = 57 (9 missing data). 
b = 2005-2008: n = 59 (7 missing data); 2009-2012: n = 54 (12 missing data). 
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Inferential Statistics 
NCHS analytic guidelines state that data from the Hepatitis C Follow-Up 
Questionnaire (HCQ) should not be used with sample weights to make national estimates 
because of small sample size and a response rate below 50% (Centers for Disease Control 
and Prevention, 2012d).  Therefore, analyses were conducted in SPSS 21.0 using chi-
square and, where appropriate (i.e. small cell sizes), Fisher’s exact tests.  Percentages 
reported are percent of respondents, not population estimates.  Results were considered 
statistically significant at the 0.05 level.   
For Research Question 1, the variables of interest were three of the HCV-positive 
participants’ responses from the Hepatitis C Follow-Up Questionnaire (HCQ).  For 
Research Question 2, the variables of interest were seven of the HCV-positive 
participants’ responses from the HCQ.  For both Research Questions 1 and 2, HCV-
positive participants were defined as those who took the screening hepatitis C anti-HCV 
test from the NHANES medical examination component, had a positive result, were 
mailed a Review of Findings letter, and completed the HCQ.  For both Research 
Questions 1 and 2, the participants were categorized into three racial/ethnic groups 
(Caucasian, African American, Hispanic/Other) and compared between two time periods, 
2005-2008 and 2009-2012.  In order to determine the independent relationship between 
the 10 HCQ responses of all participants and each racial/ethnic group in two time periods, 
the study analysis included logistic regression after controlling for the covariates of age, 
gender, race/ethnicity, education, poverty index, health insurance status, and history of 
illegal injection drug use. 
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Results for Research Question 1 
Research Question 1 was: Has the seeking of health care by HCV-positive 
African Americans improved since 2008 following the introduction of new treatment 
options as compared to other HCV-positive racial/ethnic groups?  For Research Question 
1, a chi-square test of difference, or Fisher’s exact test for small cell sizes, was conducted 
for each racial/ethnic group’s health care seeking responses between two time periods, 
2005-2008 and 2009-2012 (Table 6).  The results demonstrated no statistically significant 
difference of each racial/ethnic group’s health care seeking responses between the two 
time periods.  
Results for Research Question 2 
Research Question 2 was: Has the response from health care providers to HCV-
positive African Americans improved since 2008 following the introduction of new 
treatment options as compared to other HCV-positive racial/ethnic groups?  For Research 
Question 2, a chi-square test of difference, or Fisher’s exact test for small cell sizes, was 
conducted for each racial/ethnic group’s health care provider responses between two time 
periods, 2005-2008 and 2009-2012 (Table 6).  The results demonstrated no statistically 
significant difference of each racial/ethnic group’s health care provider responses 
between the two time periods. 
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Table 6 
 
Influence of Race/Ethnicity on Participants’ Responses, NHANES Hepatitis C Follow-Up 
Questionnaire, Time Periods 2005-2008 and 2009-2012* 
 
 2005-2008 
sample 
2009-2012 
sample 
Racial/Ethnic group   Cauc            AA             H/O   Cauc              AA             H/O 
   N   %         N    %         N     %   N      %        N      %       N     % 
Health care seeking responses       
I saw a doctor about  
the hepatitis C test resulta 
 
27  81.8    
 
15   75.0 
 
11   84.6 
 
15   83.3 
 
22   81.5 
 
17  81.0 
 
I have an appointment  
to see a doctor about  
the hepatitis C test result 
 
   
  1  16.7 
 
   
  1   20.0 
 
   
  1   50.0 
 
 
  0     0.0 
 
   
  0     0.0 
 
   
0 0.0 
1  
I decided not to get treated because: 
Side effects are unpleasant 
Need to self-inject medicine 
Too expensive 
Hope of better future treatments 
Some other reason given 
 
  4  50.0 
  2  28.6 
  5  71.4 
  3    2.9 
  5  62.5 
 
  1   50.0 
  0     0.0 
  0     0.0 
  0     0.0 
  3 100.0 
 
  1   50.0 
  0     0.0 
  1   50.0 
  0     0.0 
  1   50.0 
 
  3   50.0 
  3   60.0 
  4   66.7 
  1   20.0 
  4   66.7 
 
  1   33.3 
  1   33.3 
  1   33.3 
  1   33.3 
  2   50.0 
 
 1   20.0 
 3   60.0 
 0     0.0 
 1   20.0 
 2   40.0 
 
Health care provider responses 
      
Doctor did other blood tests  
to check the liver 
Don’t know 
 
24  88.9 
  2    7.4 
 
15 100.0 
  0     0.0 
 
10   90.9 
  0     0.0 
 
15 100.0 
  0     0.0 
 
18   85.7 
  0     0.0 
 
14  82.4 
  0    0.0 
 
Doctor told me I have hepatitis C and: 
I need regular medical follow-up 
I do not need to worry about it 
Other 
Don’t know 
 
16  59.3 
  7  25.9 
 3  11.1 
 1    3.7 
 
  8   53.3 
  6   40.0 
  0     0.0 
  1     6.7 
 
  4   40.0 
  5   50.0 
  1   10.0 
  0     0.0 
 
  9   60.0 
  0     0.0 
  5   33.3 
  1     6.7 
 
  8   38.1 
  8   38.1 
  5   23.8 
  0     0.0 
 
10  58.8 
  4  23.5 
  3  17.6 
  0    0.0 
 
I had a liver biopsy 
 
10  50.0 
   
6   66.7 
   
4   66.7 
   
8   53.3 
   
9   69.2 
   
7  53.8 
 
Doctor advised me about meds  
used to treat hepatitis C 
(such as Interferon and Ribavirin) 
 
 
17  85.0 
 
  
 8   88.9 
 
   
  5   83.3 
 
 
13   86.7 
 
 
13 100.0 
 
 
11  91.7 
 
Doctor advised me I should be treated 
 
13  76.5 
  
 5    62.5 
  
  4   80.0 
  
10   76.9 
   
  9   69.2 
   
  8  66.7 
 
I was treated with the medications 
   
  9  52.9 
 
 4    57.1 
   
  3   60.0 
   
  6   46.2 
   
  8   66.7 
   
  7  58.3 
 
Doctor told me I should not  
be treated because: 
Liver enzymes are normal 
Do not have liver disease 
Don’t need to do anything  
Wait to be treated at a later time 
No reason specified 
 
 
 
  2   50.0 
  0     0.0 
  0     0.0 
  0     0.0 
  1   25.0 
 
 
 
 0      0.0 
 0      0.0 
 0      0.0 
 2  100.0 
 0      0.0 
 
 
 
  1 100.0 
  0     0.0 
  0     0.0 
  0     0.0 
  0     0.0 
 
 
 
  1   33.3 
  1   33.3 
  1   33.3 
  1   33.3 
  1   33.3 
 
 
 
  1   50.0 
  1   50.0 
  0     0.0 
  2 100.0 
  0     0.0 
 
 
 
 1  25.0 
 1  25.0 
 0    0.0 
 1  25.0 
 1  25.0 
* = Total and percentage are “within race” categories; missing data values were not included in the 
calculations – only valid responses. 
a = test result is defined as either the participant’s first positive hepatitis C test result or the NHANES 
positive hepatitis C result. 
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Table 7 reports the frequencies and percentages for both health care seeking and 
health care provider HCQ responses of all participants in two time periods, 2005-2008 
and 2009-2012.  Missing data values were not included in the calculations, only valid 
responses defined as “yes” or “no” to the HCQ questions.  Using chi-square test of 
difference, or Fisher’s exact test for small cell sizes, between the two time periods, the 
results demonstrated no statistically significant difference of participants’ responses 
between the two time periods.  Within each time period (2005-2008 and 2009-2012) most 
participants had reported that they had seen a doctor about their hepatitis C result (80.3% 
and 81.8%, respectively) (Table 7).  Of the participants within each time period (2005-
2008 and 2009-2012) who had already seen a doctor, just over half (53.8% and 50.9%, 
respectively) reported they were told that they had hepatitis C and needed a regular 
medical follow-up.  Approximately 60% of participants within each time period (2005-
2008 and 2009-2012) reported having had a liver biopsy.  Approximately 70% of 
participants within each time period (2005-2008 and 2009-2012) reported being advised 
by the doctor that they should be treated with medications.  Just over one-half of the 
participants within both time periods (2005-2008 and 2009-2012) reported that they 
decided not to get treated because the treatment was too expensive (54.5% and 57.1%, 
respectively). 
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Table 7 
 
Participants’ Responses, NHANES Hepatitis C Follow-Up Questionnaire, Time Periods 
2005-2008 and 2009-2012* 
 
  2005 – 2008 
     Sample 
2009 – 2012 
    Sample 
 
 
    N           %   N           % P Value** 
Health Care Seeking Responses 
I saw a doctor  
about the hepatitis C test resulta 
   
  53         80.3 
 
54         81.8 
 
     NS 
I have an appointment to see a doctor  
about the hepatitis C test result 
     
   3          23.1 
   
  0           0.0 
 
     NS 
I decided not to get treated because: 
Side effects are unpleasant 
Need to self-inject medicine 
Too expensive 
Hope of better future treatments 
Some other reason given 
 
   6          50.0 
   2          18.2 
   6          54.5 
   3          27.3 
   9          69.2    
 
  5         35.7 
  4         30.8 
  8         57.1 
  3         23.1 
  8         53.3 
 
 
 
 
 
     NS 
 
Health Care Provider Responses 
   
 Doctor did other blood tests to check the liver 
Don’t know 
 49          92.5 
   2            3.8 
47         88.7 
  1           1.9 
 
     NS 
Doctor told me I have hepatitis C and: 
 I need regular medical follow-up 
I do not need to worry about it 
Other 
Don’t know 
 
 28          53.8 
 18          34.6 
   4            7.7 
   2            3.8 
 
27        50.9 
12        22.6 
13        24.5 
  1          1.9 
 
 
 
 
      NS 
I had a liver biopsy  20          57.1 24        58.5       NS 
Doctor advised me about medications  
used to treat hepatitis C  
(such as Interferon and Ribavirin) 
   
   
 30          85.7 
    
    
37        92.5 
 
 
      NS 
 Doctor advised me I should be treated  22          73.3 27        71.1       NS 
I was treated with the medications  16          55.2 21        56.8       NS 
 Doctor told me I should not be treated because: 
Liver enzymes are normal 
Do not have liver disease 
Don’t need to do anything  
Wait to be treated at a later time 
No reason specified 
 
   3          42.9 
   0            0.0 
   0            0.0 
   2          33.3 
   1          14.3 
 
  3        33.3 
  3        33.3 
  1        11.1 
  4        44.4 
  2        22.2 
 
 
 
 
 
      NS 
* = missing data values were not included in the calculation - only valid responses. 
** = P value for chi-square test of difference between time periods 2005-2008 and 2009-
2012. (Fisher’s exact test used for small cell sizes). 
NS = not significant. 
a = test result is defined as either the participant’s first positive hepatitis C test result or 
the NHANES positive hepatitis C result. 
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Logistic Regression Results 
Logistic regression was conducted to examine HCQ responses of all participants 
and each racial/ethnic group (Caucasian, African American, Hispanic/Other) within two 
4-year time periods (2005-2008 and 2009-2012), and as a pooled analysis for the total 8-
year time period of 2005 to 2012 while controlling for the covariates of age, gender, 
race/ethnicity, education, poverty index, health insurance status, and history of illegal 
injection drug use. 
2005 to 2008 time period. Table 8 contains the results from the logistic 
regression analysis for the 2005 to 2008 4-year time period for HCQ participants who 
saw a doctor about their test result.  The model wald chi-square was significant, X2(1) = 
4.018, p <0.05.  This result indicated a statistically significant association between 
having health insurance and seeing a doctor about the test result.  The odds ratio of 
537.33 (95% CI: 1.150 to 251113.35) showed that participants who had health insurance 
were 537.33 times more likely than those who did not have health insurance to see a 
doctor about their HCV-positive test result.  
Table 8 
 
Logistic Regression: Having Health Insurance Predicting Seeing a Doctor 
About the Test Result—2005-2008 
  
Predictor n Wald 
X2 
Df p OR 95% CI 
      Lower        Upper 
I have health insurance 54 4.018 1 <0.05 537.33  1.150  251113.35 
 
Table 9 contains the results from the logistic regression analysis for the 2005 to 
2008 4-year time period for HCQ participants who had a liver biopsy.  The model wald 
85 
 
chi-square was significant, X2(1) = 5.009, p <0.05.  This result indicated a statistically 
significant association between having health insurance and having had a liver biopsy.  
The odds ratio of 76.67 (95% CI: 1.715 to 3427.80) showed that participants who had 
health insurance were 76.67 times more likely than those who did not have health 
insurance to have had a liver biopsy.  
Table 9 
 
Logistic Regression: Having Health Insurance Predicting Having Had a Liver Biopsy—
2005-2008 
  
Predictor n Wald 
X2 
df p OR 95% CI 
      Lower        Upper 
I have had a liver biopsy     27 5.009 1 <0.05 76.67  1.715      3427.80 
 
2009 to 2012 time period. Table 10 contains the results from the logistic 
regression analysis for the 2009 to 2012 4-year time period for HCQ participants who 
saw a doctor about their test result.  The model wald chi-square was significant, X2(1) = 
5.065, p <0.05.  This result indicated a statistically significant association between 
having health insurance and seeing a doctor about the test result.  The odds ratio of 12.50 
(95% CI: 1.39 to 112.69) showed that participants who had health insurance were 12.5 
times more likely than those who did not have health insurance to see a doctor about their 
HCV-positive test result.  
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Table 10 
 
Logistic Regression: Having Health Insurance Predicting Seeing a Doctor About the Test 
Result—2009-2012 
 
Predictor n Wald 
X2 
df p OR 95% CI 
      Lower        Upper 
I have health insurance 48 5.065 1 < 0.05 12.50  1.39          112.69 
 
2005 to 2012 time period. Table 11 contains the results from the logistic 
regression analysis for the 2005 to 2012 8-year time period for HCQ participants who 
saw a doctor about their test result.  The model wald chi-square was significant, X2(1) = 
1.332, p <0.05.  This result indicated a statistically significant association between 
having health insurance and seeing a doctor about the test result.  The odds ratio of 12.32 
(95% CI: 2.99 to 50.80) showed that participants who had health insurance were 12.32 
times more likely than those who did not have health insurance to see a doctor about their 
HCV-positive test result.  
Table 11 
 
Logistic Regression: Having Health Insurance Predicting Seeing a Doctor About the Test 
Result—2005-2012 
 
Predictor n Wald 
X2 
df p OR 95% CI 
      Lower        Upper 
I have health insurance 102 1.332 1 <0.05 12.32  2.99           50.80 
 
Table 12 contains the results from the logistic regression analysis for the 2005 to 
2012 8-year time period for HCQ participants who have had a liver biopsy.  The model 
wald chi-square was significant, X2(1) = 6.942, p <0.05.  This result indicated a 
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statistically significant association between having health insurance and having had a 
liver biopsy.  The odds ratio of 12.69 (95% CI: 1.92 to 84.02) showed that participants 
who had health insurance were 12.69 times more likely than those who did not have 
health insurance to have had a liver biopsy.  
Table 12 
 
Logistic Regression: Having Health Insurance Predicting Having Had a Liver Biopsy—
2005-2012 
 
Predictor n Wald 
X2 
df p OR 95% CI 
      Lower        Upper 
I have health insurance 56 6.942 1 <0.05 12.69  1.92           84.02 
 
Table 13 contains the results from the logistic regression analysis for the 2005 to 
2012 8-year time period for Caucasian HCQ participants who saw a doctor about their 
test result.  The model wald chi-square was significant, X2(1) = 3.84, p = 0.05.  This 
result indicated a statistically significant association between having health insurance and 
seeing a doctor about the test result.  The odds ratio of 21.53 (95% CI: 1.00 to 463.81) 
showed that Caucasian participants who had health insurance were 12.32 times more 
likely than those who did not have health insurance to see a doctor about their HCV-
positive test result.  
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Table 13 
 
Logistic Regression: Having Health Insurance Predicting Seeing a Doctor About the Test 
Result for Caucasian Ethnicity—2005-2012 
 
Predictor N Wald 
X2 
df p OR 95% CI 
      Lower        Upper 
I have health insurance 43 3.84 1 0.05 21.53  1.00          463.81 
 
Table 14 contains the results from the logistic regression analysis for the 2005 to 
2012 8-year time period for African American HCQ participants who saw a doctor about 
their test result.  The model wald chi-square was significant, X2(1) = 3.83, p = 0.05.  This 
result indicated a statistically significant association between having health insurance and 
seeing a doctor about the test result.  The odds ratio of 59.96 (95% CI: .99 to 3263.77) 
showed that African American participants who had health insurance were 59.96 times 
more likely than those who did not have health insurance to see a doctor about their 
HCV-positive test result.  
Table 14 
 
Logistic Regression: Having Health Insurance Predicting Seeing a Doctor About the Test 
Result for African American Ethnicity—2005-2012 
  
Predictor n Wald 
X2 
df p OR 95% CI 
      Lower        Upper 
I have health insurance 35 3.83 1 0.05 56.96    .99        3263.77 
 
Based on the result of the data analyses used in this study, both stated null 
hypotheses were not rejected and it was concluded that there were no statistically 
significant associations between the health care seeking behavior and responses from 
health care providers for HCV-positive African Americans before (2005-2008) and after 
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(2009-2012) the introduction of new treatment options as compared to other HCV-
positive racial/ethnic groups.  When controlling for the covariates of age, gender, 
race/ethnicity, education, poverty index, health insurance status, and history of illegal 
injection drug use, logistic regression did reveal that having health insurance was a 
significant determinant of being likely to see a doctor for the HCV-positive test result for 
all participants in both the 4-year time periods (2005-2008 and 2009-2012), as well as all 
participants, Caucasians, and African Americans as an 8-year pooled analysis (2005 to 
2012).  Additionally, the results revealed that having health insurance was a significant 
determinant of having had a liver biopsy for all participants in the 4-year time period of 
2005 to 2008, and all participants in the 8-year pooled analysis (2005 to 2012).  The 
logistic regression did not identify any other results of statistical significance with all 
participants or each racial/ethnic group in both time periods (2005-2008 and 2009-2012) 
and as a pooled analysis (2005-2012).   
Summary 
In conclusion, the findings of this study do not support the hypotheses that there is 
a statistically significant relationship between the health care seeking behavior and 
provider responses of HCV-positive African Americans before (2005-2008) and after 
(2009-2012) the introduction of new treatment options as compared to other HCV-
positive racial/ethnic groups within the framework of the theory of planned behavior and 
theory of reasoned action model. In Chapter 5, I will interpret these results in the context 
of the current theories and understanding of HCV-positive African Americans and 
potential risk factors.  Further, I will present limitations of the study and a summary of 
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findings.  Recommendations for further research as well as the potential impact these 
findings may have on social change will be also be discussed in Chapter 5. 
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Chapter 5: Discussion 
Introduction 
The hepatitis C virus (HCV) is a major cause of liver disease, hepatocellular 
carcinoma, and end stage liver disease in the United States (Centers for Disease Control 
and Prevention, 2012a).  As previously discussed, African Americans represent only 13% 
of the U.S. population, but make up the largest racial group (22%) out of the 3.5 million 
persons infected with chronic HCV.  Disparities in access to care and treatment include a 
complex set of individual, interpersonal, socioeconomic, and environmental factors that 
influence the course of HCV infection in the African American population, resulting in 
poorer outcomes and survival.   
This research study used quantitative data from the 2005-2012 NHANES datasets.  
The purpose of this study was to determine whether the seeking of health care by HCV-
positive African Americans and the responses from health care providers to HCV-
positive African Americans have improved since 2008 following the introduction of new 
treatment options, as compared to other HCV-positive racial/ethnic groups.  To date, no 
published studies were found concerning the relationship between the seeking of health 
care and provider responses for HCV-positive African Americans before and after the 
introduction of new treatment options. 
Based on the results from the chi-square test of difference and logistic regression 
analyses conducted for hypothesis testing, I failed to reject the null hypotheses for my 
two research questions.  It was determined that the health care seeking behavior and 
health care provider responses for HCV-positive African Americans had not improved as 
of 2008 with the introduction of new treatment options, as compared to other HCV-
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positive racial/ethnic groups.  The results from the logistic regression revealed that all 
participants in both of the 4-year time periods studied (2005-2008 and 2009-2012) who 
had health insurance were more likely to see a doctor for their HCV-positive test result.  
These same results were also found in the 8-year pooled analysis (2005-2012) with all 
participants, Caucasians, and African Americans.  Additionally, the results revealed that 
all participants in the 4-year time period of 2005 to 2008, and all participants in the 8-
year pooled analysis (2005-2012) who had health insurance were more likely to have had 
a liver biopsy. 
Interpretation of the Findings 
Overall, the findings of this study indicated that there had not been any 
improvement in the health care seeking behavior and provider responses for HCV-
positive African Americans or other HCV-positive racial/ethnic groups since 2008 with 
the introduction of newer treatment options.  Participants in the 2005-2008 time period 
were more likely to be younger than age 50 (p < 0.05) and Caucasian (p < 0.05) as 
compared to participants in the 2009-2012 time period.  In comparing each of the 
racial/ethnic groups between the two time periods, the Hispanic/Other group in the 2005-
2008 time period was more likely to be younger than 50 years of age (p < 0.05) as 
compared to the Hispanic/Other group in the 2009-2012 time period.  A statistically 
significant relationship did not exist with each of the racial/ethnic group’s (Caucasian, 
African American, Hispanic/Other) responses to the Hepatitis C Follow-Up 
Questionnaire (HCQ) between two time periods (2005-2008 and 2009-2012).  Eighty-one 
percent of the study sample reported that they had seen a doctor about their past or 
current HCV infection, with 51% having reported being told that they had hepatitis C and 
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needed a regular medical checkup.  Although approximately 70% of all participants were 
told that they should be treated with medications, of those who had decided not to get 
treated, 58% had reported that this was because the treatment was too expensive.   
With the inclusion of sociodemographic covariates in the regression models, 
results indicated significant associations with participants who had health insurance.  
Having health insurance, while controlling for other variables, was significantly 
associated with the HCQ response of “I have seen a doctor about my test result”.  This 
was evident in all participants in both time periods (2005-2008 and 2009-2012), and as a 
pooled analysis (2005-2012) with all participants, and both Caucasian and African 
American racial/ethnic groups.  In addition, having health insurance, while controlling for 
other variables, was significantly associated with the HCQ response of “I had a liver 
biopsy”.  This was evident in all participants in both the 2005 to 2008 4-year time period, 
and as an 8-year pooled analysis (2005-2012).  A total of 72% of the study sample had 
health insurance, with 58% reporting having had a liver biopsy; and, as previously 
discussed, 81% of the study sample reported having seen a doctor about their past or 
current HCV infection.   
These findings are consistent with those of researchers who examined the impact 
of having health insurance coverage.  Turner et al. (2013) surveyed 600 injection drug 
users in New York City and found that African Americans were less likely to have visited 
a private medical office in the past year, whereas those with higher income and health 
insurance coverage were more likely to visit a private medical office.  Melia et al. (2011) 
found that HCV-positive African Americans are disproportionately affected by lack of 
adequate health insurance and high treatment costs.  Gordon et al. (2015) found that 
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having private health insurance coverage was associated with lower odds of cirrhosis in 
hepatitis C patients.   
Limitations of the Study 
There were several limitations to this study.  The NHANES survey is cross-
sectional by design.  Limitations of using successive cross-sectional survey data over 
time include: (a) reliance on the continuity of the data, (b) inability to establish individual 
change, and c) inability to determine a causal relationship (King-Hele, 2005).  As 
NHANES data were collected at one point in time, longitudinal trends in health behavior 
cannot be examined.  Selection bias and sampling bias may be limitations of the study; 
however, the NHANES survey uses a complex, stratified, multistage probability 
sampling procedure to minimize this potential risk (Centers for Disease Control and 
Prevention, 2013a).  Although the Hepatitis C Follow-Up Questionnaire (HCQ) is nested 
within the NHANES, the data from the HCQ cannot be used to generate population 
estimates because of the small number of respondents and low response rate.  
Frequencies for some questions may be affected by differences in characteristics of HCQ 
participants versus nonparticipants.  In addition, the small sample size limited the power 
to detect statistically significant differences between subgroups.  Lastly, as the data are 
self-reported, another limitation is the usual biases associated with such data (e.g., recall 
bias and/or information bias), including the possibility of participants not understanding 
questions regarding medical information, such as whether they had a particular medical 
procedure or blood test performed or what they had been told by a health care provider.   
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Recommendations 
This study reported results for a sample of NHANES participants who responded 
to a follow-up questionnaire after having tested positive for past or current HCV infection 
from 2005 through 2012, which, to my knowledge, is the only questionnaire of such 
individuals to be conducted as part of a national population-based study.  Overall, the 
study did not find any significant improvements in the health care seeking behavior or 
provider responses for HCV-positive African Americans since 2008 after the introduction 
of new treatment options as compared to other HCV-positive racial/ethnic groups.  The 
landscape and discovery of new and improved direct-acting antivirals (DAAs) to treat 
HCV infection are continuing to evolve into regimens with shorter durations, better 
tolerability, and higher cure rates.  During the time period in which the first-generation 
DAAs were available and being used to treat HCV-infected individuals, there already 
existed ongoing studies of second-generation DAAs that demonstrated even better 
tolerability and efficacy.  In these studies, even higher rates of sustained viral response or 
cure (89%-90%) have been demonstrated in treatment-naïve patients as compared to first-
generation agents (Kohli, Shaffer, Sherman, & Kottilil, 2014).  In addition, one study 
conducted in 2013 found that 90% of physicians in the United States reported that they 
were “warehousing” patients (holding off treatment) in expectation of more efficacious 
and tolerable new therapies (Taylor, 2013).  As of 2015, there is currently a total of six 
second-generation DAAs that have been approved and are being used (alone or in 
combination) for the treatment of HCV infection (U.S. Food and Drug Administration, 
2014).  With second-generation DAAs providing improvements in efficacy and 
tolerability across all racial/ethnic groups, further research might focus on the HCV-
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infected population as a whole to determine whether differences exist in health care 
seeking behavior and provider responses as compared to the first-generation DAAs. 
Additional research may also be needed to evaluate strategies to enhance assessment, 
adherence, and treatment responses among those at risk, including special populations, 
particularly as new treatments for HCV infection continue to become available. 
Due to the close association between a person having health insurance coverage 
and seeing a doctor and/or having a liver biopsy, future research efforts might focus on a 
closer examination of health insurance status as a predictor for seeking medical care 
and/or getting medical procedures in different clinical settings.  In addition, over one-half 
of the study participants who decided not to get treated with medications reported that it 
was because the HCV treatment was too expensive.  Obamacare’s individual mandate 
required most Americans to obtain health insurance by January 1, 2014 
(obamacareusa.org, 2015).  Future research might also examine the potential association 
that health insurance coverage has on the screening and preventive care efforts for 
hepatitis C, as well as treatment and outcomes. 
Implications for Social Change 
These research findings suggest that more intensive efforts are needed to identify 
and test those at risk for HCV infection and the need to educate patients and providers 
about appropriate interaction on prevention decisions and actions.  Prior to this study, no 
previously published study had compared the health care seeking behavior and provider 
responses of HCV-positive African Americans before the introduction of new treatment 
options (2005-2008) and after the introduction of new treatment options (2009-2012) as 
compared to other HCV-positive racial/ethnic groups.  HCV infection remains a critical 
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public health challenge in the African American population.  African Americans are most 
at risk for infection and transmission due to illegal injection drug use behavior, in 
addition to worse health outcomes to include increased morbidity and mortality.  Positive 
social change may happen by emphasizing the awareness of the risks of HCV infection, 
reducing provider bias, removing barriers to care, and introducing resources into the 
African American and underserved communities; as a result, there may be improvements 
in screening, treatment, and outcomes.  The findings of this study may aid public health 
professionals in the design of public health policies, educational programs, and screening 
and treatment recommendations that could lead to positive social change among the 
groups most at risk for hepatitis C infection.    
Prevention is the key to reducing the risk of HCV transmission. The findings of 
this study may impact change socially by increasing public communication within the 
African American communities which would raise awareness of the risks of HCV 
infection; as well as the potential implementation of local neighborhood-level clinics, 
syringe exchange programs, and additional resources in the lower and poor communities 
to improve access to health care and outcomes for this afflicted population. 
Conclusion 
To my knowledge, this study was the first study to explore the association 
between the health care seeking behavior and provider responses for HCV-positive 
African Americans before and after the introduction of new treatment options as 
compared to other HCV-positive racial/ethnic groups.  Results from the study did not 
identify a statistically significant relationship of health care seeking behavior and 
provider responses between the two time periods.  With regard to analyzing the 
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covariates, the study did identify a significant association between having health 
insurance coverage and seeing a doctor about the HCV test result and/or having a liver 
biopsy.  The findings from this study add to the body of knowledge by quantifying the 
association between the health care seeking behavior and provider responses over an 8-
year period collectively and within each racial/ethnic group (Caucasian, African 
American, Hispanic/Other).   
There have been numerous approaches to prevention and intervention of HCV 
infection.  The identification, counseling, and testing of persons at risk should be a top 
priority. The National Prevention Information Network provides persons and health care 
professionals with the most current information, resources, and tools to support your 
organization’s efforts to prevent viral hepatitis; as well as links to find hepatitis C 
providers/clinics in a specific area for networking, and access to federal and private 
funding opportunities (Centers for Disease Control and Prevention, 2012).  All of these 
resources can be beneficial to educate the healthcare professional on persons at risk for 
HCV, and who should be screened, plus access to patient-centric educational resources. 
For the African American population, increasing awareness and knowledge 
among health care providers and communities about hepatitis C infection, and improving 
access to quality prevention, research trials, care, and treatment services, while 
eliminating disparities is essential.  With the landscape and discovery of new and 
improved drugs to treat HCV infection continuing to evolve into regimens with shorter 
durations, better tolerability, and higher cure rates, the findings of this study lay the 
groundwork for researchers to comparatively assess any improvement or changes in 
health care seeking behavior and provider responses by HCV-infected populations 
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moving forward.  The results of this study do not support the hypotheses that the health 
care seeking behavior and health care provider responses for HCV-positive African 
Americans has improved as of 2008 with the introduction of new treatment options, as 
compared to other HCV-positive racial/ethnic groups.   
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